Single-molecule Biomechanics of von Willebrand Factor A-domains by Xu, Yan
Lehigh University
Lehigh Preserve
Theses and Dissertations
2015
Single-molecule Biomechanics of von Willebrand
Factor A-domains
Yan Xu
Lehigh University
Follow this and additional works at: http://preserve.lehigh.edu/etd
Part of the Mechanical Engineering Commons
This Dissertation is brought to you for free and open access by Lehigh Preserve. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Xu, Yan, "Single-molecule Biomechanics of von Willebrand Factor A-domains" (2015). Theses and Dissertations. 2889.
http://preserve.lehigh.edu/etd/2889
Single-molecule Biomechanics of von Willebrand Factor 
A-domains  
 
 
by 
 
 
Yan Xu 
 
 
 
 
 
 
A Dissertation 
 
Presented to the Graduate and Research Committee 
 
of Lehigh University 
 
in Candidacy for the Degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
in 
 
 
Mechanical Engineering 
 
 
Lehigh University 
 
 
May 2015
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright 2015 © by Yan Xu 
 
All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
Approved and recommended for acceptance as a dissertation in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy 
 
Name: Yan Xu 
 
Dissertation Title: Single-molecule Biomechanics of von Willebrand Factor 
A-domains 
 
 
 
 
                                                 
Defense Date 
 
 
                                                                     
         Dr. Xiaohui (Frank) Zhang, Dissertation Director, Chair 
            
 
                                                                                                 
Approved Date    
                                                                  
                                                                       
 
        Committee Members: 
 
 
 
                                                                      
        Dr. Alparslan Oztekin 
 
 
                                                                      
        Dr. Xuanhong Cheng 
 
 
                                                                      
        Dr. Edmund Webb III  
 
 
                                                                      
        Dr. Chao Zhou 
 
 
iv 
ACKNOWLEDGEMENTS 
PhD Advisor 
Dr. Xiaohui (Frank) Zhang: for the solid support, inspiring guidance, generous help and 
heartwarming encouragement, also for being an amazing mentor, an outstanding scientist 
and an endearing friend.  
Doctoral Committee 
Dr. Alparslan Oztekin: for joyful discussions, brilliant ideas and input to my work, the 
enthusiasm in research and for the awesome Christmas party every year.   
Dr. Xuanhong Cheng: for coaching me in microfluidic devices, showing me what a 
capable researcher should be and countless help to me.   
Dr. Edmund Webb III: for passionate discussions, critical questions and humorous but 
inspiring commands.   
Dr. Chao Zhou: for teaching me in biophotonics, allowing me to run some experiments 
with his facilities, also for the tremendous help in my job searching.  
Collaborators and Lab mates 
Dr. Thomas A. J. McKinnon, Dr. Renhao Li, Dr. Yizhen Wang, Dr. Bu Wang, Dr. Ming-
Tzo Wei, Dr. Wenli Ouyang, Dr. Rachael Barton, Logan MacDonald, Fengqiang Li, 
Matthew Dragovich, Chenyu Wu, Wei Zhang, Yan Guo, Wei Wei, Haoling Ma, Chelsea 
 
 
v 
Coffey, Ohmny Romero, Krista Schutt, Jing Liu, Yu Song, Caroline Multari, and Chao 
Zhao for kindly sharing materials, devices and expertise.  
Family and Friends 
Quanxi Xu and Chunrong Ma: my dearest parents who have trusted and supported me all 
this time, giving me everything they have and missing me wherever I am.  
Shuo Zhang, Dr. Amit Belwalkar, Dr. Yartin S Karpe, Thomas Meischeid, Marie A. 
Bartos, Brian Flynn, Dr. Xiao Liu, Dr. Yi Hu, Dr. Qian Wu, Dr. Zhen Peng, Dr. Guan 
Sun, Dr. Xu Li, Dr. Shanshan Liu, Dr. Chao Xu, Dr. Yang Yu, Bo Lin, Tianyi Luo, Ran 
Huang, Bo Han, Kanlun Li, Zhou Yang, Yuanyuan Wang and Yi Chen, for being so nice 
and helpful to me, also for sharing both the happiness and sadness of life with me. 
George Lyons Sensei, Patti Lyons Sensei and all the Bucks County Aikido members, for 
not only training my techniques and strength in AIKIDO, but also taking care of me like 
family. 
 
 
 
 
 
 vi 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ........................................................................................... IV 
TABLE OF CONTENTS ............................................................................................... VI 
LIST OF FIGURES ......................................................................................................... X 
LIST OF TABLES ....................................................................................................... XIII 
ABSTRACT ....................................................................................................................... 1 
CHAPTER 1 ...................................................................................................................... 3 
INTRODUCTION ............................................................................................................ 3 
1. MOTIVATION- VON WILLEBRAND DISEASE (VWD) ..................................................... 3 
2. ABOUT VON WILLEBRAND FACTOR (VWF) .................................................................. 4 
2.1. Biosynthesis of VWF ............................................................................................ 4 
2.2. Domain structure and function .............................................................................. 5 
2.3. Hemostasis and thrombosis ................................................................................... 7 
3. FACILITIES AND DEVICES ............................................................................................ 10 
3.1. Atomic Force Microscope (AFM) ....................................................................... 10 
3.2. Miniature Optical Tweezers ................................................................................ 15 
3.3. Microfluidic Device ............................................................................................ 17 
CHAPTER 2 .................................................................................................................... 20 
 vii 
BIOMECHANICAL CHARACTERIZATION OF VWF-COLLAGEN 
INTERACTION .............................................................................................................. 20 
1. INTRODUCTION ........................................................................................................... 20 
2. MATERIALS AND METHODOLOGY ............................................................................... 22 
2.1. Samples and Materials ........................................................................................ 22 
2.2. Setup the Atomic Force Microscope (AFM) ....................................................... 23 
2.3. Coating the Probes .............................................................................................. 25 
3. RESULTS AND DISCUSSION ......................................................................................... 32 
3.1. Experimentally Measure the Rupture Force and loading Rate for Dynamic Force 
Spectrum ..................................................................................................................... 32 
3.2. Adhesion Percentage and Control Group ............................................................ 36 
3.3. Identify The Most Probable Rupture Force Under Each Pulling Speed. ............ 38 
3.4. Fitting Data with The Bell- Evans Model ........................................................... 40 
3.5.  Utilize AFM Unbinding Assay to Define The Force Spectrum for Mutant VWF 
Multimers ................................................................................................................... 47 
4. CONCLUSION .............................................................................................................. 54 
CHAPTER 3 .................................................................................................................... 57 
IDENTIFICATION OF A JUXTAMEMBRANE MECHANOSENSITIVE 
DOMAIN IN THE PLATELET MECHANOSENSOR GLYCOPROTEIN IB-IX 
COMPLEX ...................................................................................................................... 57 
1. INTRODUCTION ........................................................................................................... 57 
2. MATERIALS AND METHODOLOGY ............................................................................... 60 
2.1. Biotinylated GPIb-IX complex ........................................................................... 60 
 viii 
2.2. VWF A1 Domain ................................................................................................ 61 
2.3.  Antibodies .......................................................................................................... 61 
2.4.  Botrocetin ........................................................................................................... 61 
2.5.  DNA Handles ..................................................................................................... 61 
2.6.  Beads for Optical-tweezers ................................................................................ 62 
2.7 Setup for the Pulling Assay on The Optical-Tweezers Platform ......................... 63 
3. RESULTS AND DISCUSSION ......................................................................................... 65 
3.1. Optical-tweezers Unfolding Assay on VWF A1 Domain-GPIb-IX .................... 65 
3.2. Locate the Mechanosensitive Domain (MSD) within GPIb-IX Complex .......... 66 
3.3. Measure the Enhancement of Botrocetin on VWF A1 Domain-GPIb-IX Complex 
Interaction ................................................................................................................... 70 
4. CONCLUSION .............................................................................................................. 72 
CHAPTER 4 .................................................................................................................... 74 
BIOMECHANICAL PROPERTIES OF VON WILLEBRAND FACTOR (VWF) 
MULTIMER .................................................................................................................... 74 
1. INTRODUCTION ........................................................................................................... 74 
2. MATERIALS AND METHODOLOGY ............................................................................... 75 
2.1. VWF multimer .................................................................................................... 75 
2.2. Microfluidic Flow Chamber ................................................................................ 75 
3. RESULTS AND DISCUSSIONS ........................................................................................ 77 
3.1. Unfolding the VWF Multimer with Atomic Force Microscope (AFM) ............. 77 
3.2. Characterization of the Interaction between VWF and Collagen under Shear 
Flow ............................................................................................................................ 78 
 ix 
3.3. Characterization of the Domain-Domain Interactions within the VWF Multimer
 .................................................................................................................................... 81 
4. CONCLUSION .............................................................................................................. 86 
CONCLUDING REMARKS AND OUTLOOK .......................................................... 88 
BIBLIOGRAPHY ........................................................................................................... 91 
VITA ................................................................................................................................ 99 
 
  
 x 
LIST OF FIGURES 
FIGURE 1. STRUCTURE OF VWF TUBULES AND THE WPB MEMBRANE. ............................... 5 
FIGURE 2. FIVE STRUCTURAL DOMAINS OF VON WILLEBRAND FACTOR (VWF) .................. 6 
FIGURE 3. A. SCHEMATIC OF THE HOMEBUILT AFM. B. TYPICAL AFM PULLING CURVES 
USING TITIN I27. ......................................................................................................... 10 
FIGURE 4. A. AFM CANTILEVERS. B. SCHEMATIC OF AN AFM CANTILEVER TIP. (REPRINTED 
FROM BRUKER WEBSITE). ............................................................................................ 11 
FIGURE 5. A. OPTICAL TWEEZERS. B. FLUIDIC SETUP OF MINIATURE OPTICAL TWEEZERS. C. 
OPTICAL LAYOUT OF MINIATURE OPTICAL TWEEZERS (REPRINTED FROM 
HTTP://TWEEZERSLAB.UNIPR.IT/CGI-BIN/MT/HOME.PL). ............................................... 16 
FIGURE 6. SCHEMATIC OF THE HOMEBUILT MICROFLUIDIC DEVICE. B. PICTURE OF THE 
WAFER USED TO MAKE PDMS MICROFLUIDIC DEVICES. C. DEVICE ASSEMBLED ON 
GLASS SLIDE WITH INLET AND OUTLET PUNCHED. ........................................................ 17 
FIGURE 7. SCHEMATIC OF THE HOMEBUILT AFM WITH IMPLEMENTATION OF THERMO 
CONTROL COMPONENT. ............................................................................................... 25 
FIGURE 8. OXIDATION AND GAS PHASE APTES SILANIZATION OF SILICAON NITRIDE TIPS . 26 
FIGURE 9. REACTION OF NHS-AMINO GROUP THAT CONVERTS ACETAL INTO ALDEHYDE. . 28 
FIGURE 10. SCHEMATIC OF THE UNBINDING ASSAY SETUP.. ............................................... 30 
FIGURE 11. TYPICAL PULLING CURVES PLOTTED BY IGOR SOFTWARE ............................... 35 
FIGURE 12. CONTROL EXPERIMENT GROUP. ....................................................................... 37 
FIGURE 13. HISTOGRAMS OF THE RUPTURE FORCE FOR VWF MONOMER-COLLAGEN 
UNBINDING . ................................................................................................................ 38 
 xi 
FIGURE 14. HISTOGRAMS OF THE RUPTURE FORCE FOR VWF A3 DOMAIN-COLLAGEN 
UNBINDING.. ................................................................................................................ 39 
FIGURE 15. DYNAMIC FORCE SPECTRUM OF VWF MONOMER-COLLAGEN AND VWF A3 
DOMAIN-COLLAGEN WITH FITTED BELL MODEL PARAMETERS. .................................... 43 
FIGURE 16. COMPARISON OF BOND LIFETIME AS A FUNCTION OF THE FORCE OF A3-
COLLAGEN INTERACTIONS, A1-GPIBα INTERACTIONS AND A2 UNFOLDING. .............. 45 
FIGURE 17. RIBBON DIAGRAM OF THE VWF WITH MUTANT A3 DOMAIN.. ......................... 47 
FIGURE 18. DYNAMIC FORCE SPECTRUM OF WT VWF-COLLAGEN INTERACTIONS, 
INCLUDING WT VWF MULTIMER, VWF MONOMER AND VWF A3 DOMAIN. .............. 49 
FIGURE 19. DYNAMIC FORCE SPECTRUM OF NEM TREATED VWF-COLLAGEN INTERACTION, 
COMPARING WITH WT VWF MULTIMER. .................................................................... 51 
FIGURE 20. DYNAMIC FORCE SPECTRUM OF S1731T VWF MUTATION (GREEN) AND 
W1745C VWF MUTATION (ORANGE), COMPARING WITH WT VWF MULTIMER (BLUE).
 .................................................................................................................................... 52 
FIGURE 21. TYPE I COLLAGEN WITH VWF: AG ELISA. ERROR BARS REPRESENT MEAN ±SD 
OF 3 SEPARATE EXPERIMENTS PERFORMED IN DUPLICATE [22]. ................................... 53 
FIGURE 22. DYNAMIC FORCE SPECTRUM OF ALL THE SAMPLE PAIRS: WT MULTIMER VS. 
COLLAGEN (BLUE), A3 DOMAIN VS. COLLAGEN (RED), WT MONOMER VS. COLLAGEN 
(BLACK), NEW TREATED VWF VS. COLLAGEN (PINK), S1731T VWF MUTATION VS. 
COLLAGEN (GREEN) AND W1745C VWF MUTATION VS. COLLAGEN (ORANGE). ......... 55 
FIGURE 23. RIBBON STRUCTURES OF THE VWF-GPIB-IX COMPLEX BINDING [78]. ........... 58 
FIGURE 24. DIAGRAM OF THE OPTICAL-TWEEZERS SETUP [76]. .......................................... 64 
FIGURE 25. TYPICAL UNFOLDING CURVE OF VWF A1 DOMAIN-GPIB-IX [76]. ................. 65 
 xii 
FIGURE 26. UNFOLDING CURVES OF GPIB-IX WITH WM23 AND 5G6 ANTIBODIES. ........... 67 
FIGURE 27. AVERAGE UNFOLDING EXTENSION OF GPIB-IX PULLED BY WM23 AND 5G6. 68 
FIGURE 28.  SCHEMATIC OF A PROPOSED MODEL SHOWING THE MECHANOSENSITIVE 
MECHANISM OF GPIB-IX [76]. .................................................................................... 69 
FIGURE 29. HISTOGRAMS OF THE RUPTURE FORCE WHEN UNBINDING VWF MONOMER FROM 
GPIB-IX WITH AND WITHOUT BOTROCETIN. ................................................................ 70 
FIGURE 30. LIFETIME (S) VERSUS RUPTURE FORCE (PN) OF VWF MONOMER-GPIB-IX 
WITHOUT (TOP) AND WITH (BOTTOM) BOTROCETIN. .................................................... 71 
FIGURE 31. UNFOLDING THE PLASMA AFM MULTIMER. A. AFM FORCE-EXTENSION CURVE 
OF VWF MULTIMER. B. AFM FORCE-EXTENSION CURVE OF VWF MONOMER. ........... 77 
FIGURE 32. MICROFLUIDIC SYSTEM TO ACHIEVE CONTROLLABLE FLOW FIELD. .............. 79 
FIGURE 33. SCHEMATIC OF DOMAIN-DOMAIN INTERACTIONS. ........................................... 81 
FIGURE 34. SCHEMATIC OF THE ANTIBODY-BASED PULLING ASSAY. .................................. 82 
FIGURE 35. PULLING VWF MONOMER WITH THE ANTIBODY-BASED PULLING ASSAY. ....... 85 
  
 xiii 
LIST OF TABLES 
TABLE 1. CLASSIFICATION AND SUMMARY OF VON VILLEBRAND DISEASE (VWD). ........... 4 
TABLE 2. SPECIFICATION OF AFM CANTILEVER (BRUKER). .............................................. 12 
TABLE 3. SPECIFICATION OF AFM CANTILEVER TIPS (BRUKER). ....................................... 12 
TABLE 4. SPECIFICATION OF THE VWF SAMPLES. ............................................................. 22 
TABLE 5. PRESET PARAMETERS OF THE AFM .................................................................... 33 
TABLE 6. SUMMARY OF THE BELL MODEL PARAMETERS FOR EACH SAMPLE IN THE 
UNBINDING ASSAY. ..................................................................................................... 56 
TABLE 7. COMPARISON OF THE DUDKO MODEL FITTED PARAMETERS BEFORE AND AFTER 
ADDING BOTROCETIN .................................................................................................. 72 
 
 
 
 
 
 
 1 
ABSTRACT 
        von Willebrand Factor (VWF) is a polymeric plasma glycoprotein which is very 
important for the hemostasis of bleeding blood vessels. When blood vessels are injured, 
the hydrodynamic force in the bloodstream experiences a sharp increase and the stability 
of the flow field is disturbed simultaneously. However, von Willebrand factor (VWF), by 
bridging over platelets and exposed collagen, forms hemostatic plugs to stop bleeding. 
Responding to the high shear rate in the blood stream, the multimeric VWF wisely alters 
its conformation from the original compact-like coil to a thread-like shape and exposes as 
many functional domains as possible, to secure increased binding strength with collagen 
and higher capturing efficiency with platelets. During the entire process of hemostasis 
and thrombosis, the A-domains, including A1, A2 and A3, behave as the most influential 
function group within VWF.  
        A single-molecule study is an experiment that investigates the properties of 
individual molecules. It has been increasingly utilized into biological studies since late 
1980s. The main reasons that single-molecule study can be implemented into biological 
applications are as follows: first, it is a very direct method that performs precise 
measurement on the most fundamental parameters (e.g. force, strength, stiffness) of the 
biological sample; second, the single-molecule study is conducted in real time, hence it 
enables simultaneous observation that perfectly fulfills demands to record certain 
biological phenomena (e.g. morphology, stimulation, conformational change); third, it 
can achieve outstanding resolution and sensitivity, which make single-molecule studies 
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an ideal method to characterize both the structural and functional properties for 
biomolecules such as  cells and tissue both intermolecularly and intramolecularly.  
        Within this dissertation, two single-molecule devices: atomic force microscope and 
optical tweezers are employed to study the A-domains of von Willebrand factor (VWF). 
First, the interaction between VWF and collagen has been comprehensively characterized 
in domain, monomer and multimer phases. Meanwhile, a quantitative comparison has 
been given to identify the functional defects of different mutations of von Willebrand 
Disease (VWD). Second, the adhesiveness between VWF and glycoprotein1 (GP1) 
receptor on the platelet membrane has been studied carefully to unveil the mechanism of 
hemostasis and thrombosis. Similarly, the mutant VWF with defects in platelet binding 
has been examined. Third, based on the first two experiments, another set of experiments 
has been done on multimeric VWF protein. A new assay method by using two different 
VWF antibodies to measure intra-molecular interactions within the VWF multimer on the 
platform of optical tweezers was developed. 
         Throughout the entire study, the A1, A2 and A3 domains within VWF are discussed 
comprehensively from both functional and structural perspectives. Meanwhile, the data 
from wild type samples are always compared with the ones from mutations. Therefore, 
the structural defects are connected with the functional ineffectiveness. Finally, based on 
the result of this dissertation, several diagnostic solutions are proposed. 
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CHAPTER 1  
Introduction 
1. Motivation- von Willebrand Disease (VWD) 
       von Willebrand Factor (VWF) has been a subject of research interest since last 
century, because it is the root cause of von Willebrand Disease (VWD). VWD (found in 
1926; named after Erik Adolf von Willebrand) is the most common hereditary 
coagulation abnormality reported in humans. Statistically, one in 100 individuals has a 
functional defects or no/low expression of the von Willebrand factor (VWF), but the 
majority of them have relatively mild symptoms. Therefore, the prevalence of VWD with 
clinical significance is about one per 10,000 [1]. The more severe VWD patients are 
proportionally more likely to be female. Additionally, those with O blood type are more 
likely to suffer from severe and apparent symptoms. Obvious symptoms are usually in the 
form of easy bruising, nosebleeds, bleeding gums, heavy menstrual periods, and blood 
loss during childbirth. Based on clinical observation and pathology studies, there are 
three general types of hereditary von Willebrand Disease: VWD Type 1, VWD Type 2, 
and VWD Type 3. Within each type, there are various subtypes [2-4]. The most common 
types of VWD are classified and summarized as in Table 1 below. While the 
development of new diagnostic techniques has promoted the discovery of more new 
subtypes, a therapeutic solution to cure VWD has not been fully established. Nowadays, 
the main treatment for severe VWD patients is still blood infusion.  
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Table 1. Classification and Summary of von Villebrand Disease (VWD). 
Type Description VWF Prevalence 
1 
Bleeding following surgery, 
noticeable easy bruising, or 
menorrhagia 
Heterozygous for the 
defective gene, decreased 
production 
70%-80% 
2 
2A 
Ristocetin co-factor activity is 
low and reduced or absent 
large VWF multimers 
Qualitatively defective, 
decreased platelet binding 
and multimerization 
10%-15% 
2B Thrombocytopenia Abnormally enhanced platelet binding ≈5% 
2M High molecular weight large VWF multimers 
Decreased platelet binding 
and normal multimerization Rare 
2N Quantitatively decreased coagulation factor VIII 
Deficiency of coagulation 
factor VIII binding Rare 
3 Extremely low Factor VIII level 
Complete absence of VWF 
production  Rare 
 
 
2. About von Willebrand Factor (VWF) 
2.1. Biosynthesis of VWF 
        von Willebrand Factor (VWF) is a polymeric plasma glycoprotein critical for 
hemostasis of bleeding. von Willebrand Factor has a very unique structure, which enables 
it to assemble during biosynthesis into helical tubules and then be stored for rapid 
exocytic release in Weibel-Palade bodies (WPB) [5]. During the biosynthesis process, the 
VWF glycoprotein is first synthesized as pre-propeptide [5, 6]. Following the removal of 
the signal sequence, the pre-propeptide is transferred into the endoplasmic reticulum (ER) 
[7]. Afterwards, the N-linked glycans are introduced into the ER and help construct the 
inter-monomer disulphide bonds in the C-terminal cystine-knot (CK) domain. 
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Consequently, VWF monomers are assembled into dimers in the endoplasmic reticulum 
by crosslinking of cysteine residues. Finally, the molecules are translocated to Golgi, 
where the propeptide is modified by O-linked glycans to form the multimeric structure 
[6]. The multimers are condensed and stored in Weibel-Palade Bodies (WPB) in the 
shape of helical tubules [8]. As shown in Figure 1a, a so called paracrystal structure has 
been reported based on the Cryo-EM study on Weibel-Palade Bodies[8].  
 
 
Figure 1. Structure of VWF tubules and the WPB membrane. a. Cryo-EM section of a 
tomogram showing segmentation contours for membranes (red: WPB membrane). b. 
Model of VWF tubules and WPB membrane. The yellow tubules represents full-length of 
the granule, orange shows the bending part and shorter ones are marked in blue. c. 250 Å 
projected tomogram cross-section at dashed black line in b [8]. 
 
2.2. Domain structure and function 
        VWF precursor (pro-VWF) has a molecular weight of about 350 kDa. It is 
synthesized with a signal peptide and five structural domains arranged in the order of D1-
D2-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (Figure 2) [5]. When the vessel is 
injured, the D1 and D2 domains are trimmed off. Disulfide bonds are formed in D’-D3 
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domain to form mutimers. Another very important property of D’-D3 domain is the 
binding affinity with Factor VIII (FVIII), an essential coagulation factor in blood [9]. 
FVIII circulates in the blood stream after being produced in the liver, and binds onto the 
D’-D3 domain of von Willebrand Factor under a normal condition. As soon as the vessel 
is injured, FVIII is immediately activated and unbinds from D’-D3 domain of VWF to 
initiate blood clotting. On the other end of the mature VWF monomer, the C domain 
binds with activate platelet integrin αIIbβ3 [10]. This interaction initiates the interposition 
of VWF multimer and platelet, which prepares for the strengthened binding between the 
platelet glycoprotein Ib (GPIb) and the VWF A1 domain in the later step of hemostatic 
plug formation [11].   
 
 
Figure 2. Five structural domains of von Willebrand Factor (VWF) [5]. 
 
         This dissertation will focus on studying the A-domains of VWF. The A1 domain is 
know to bind with a membrane glycoprotein Ib (GPIb) on platelets. At the same time, 
researchers suspect that the A1 domain also binds with collagen fibers to initialize the 
immobilization of VWF [12]. The A2 domain contains no disulfide bonds, so that it can 
be unfolded when subjected to pulling force. As unveiled by Zhang, et al. in [13], the A2 
domain demonstrates outstanding elasticity that responses to the hydrodynamic force 
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simultaneously. More interestingly, the A2 domain acts as a safety factor, which cleaves 
itself while exceed platelets attach on during the blood clotting process [5, 13, 14]. The 
studies by Zhang and Springer show a self-truncation mechanism during the formation of 
hemostatic plugs. The metalloprotease ADAMTS13 cleaves the Tyr1605-Met1606 bond [13, 
15] when the A2 domain is stretched. The A3 domain works as an anchor to fix the VWF 
onto exposed collagen (types I, III, and VI) of sub- endothelial matrix when the vessel is 
injured, so it is extremely essential [16] to determine the efficiency of the hemostatic plug 
formation.   
 
2.3. Hemostasis and thrombosis 
        In human body, the blood is circulating in the healthy vessels. The red blood cells 
predominate in the axial stream, due to the hydrodynamic force gradient, while biconvex 
disc-shaped platelets are marginated to move along the vessel wall. Thus, platelets are at 
an optimal position to closely monitor the integrity of the endothelial cells of the vessel 
wall. Normal endothelial cells expose a non-adhesive surface to blood flow. When the 
vessel wall is injured and the endothelial cells are damaged, the sub-endothelial matrix 
that contains rich collagen fibers is exposed to blood and initiates the binding of platelets 
to form a hemostatic plug. Platelet binding is initiated via a collagen receptor, integrin 
α2β1 (GPIa-IIa) on the membrane. Afterwards, the binding is strengthened via the GPVI 
receptor.  
        Adhesion of platelets to the exposed sub-endothelium is influenced dramatically by 
shear rates [17]. When the shear rate reaches a very high level, e.g. in small arteries, 
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initial binding of platelets to collagen by α2β1 and GPVI doesn’t generate sufficient 
adhesion. In this scenario, von Willebrand Factor released from Weibel-Palade bodies 
(WPB) starts to play an essential role. It immobilizes on collagen fibers and bridges with 
the GPIb-IX-V receptor on the platelet membrane. In the second stage of platelet 
adhesion, platelets aggregate and undergo dramatic metamorphosis by extruding multiple 
filopodia to increase their surface contact area on the sub-endothelial matrix.  
        VWF binding on collagen is mainly triggered by its conformational change. S. W. 
Schneider in [17] concludes that there is a threshold shear rate that determines the start of 
the dominant conformational stretch. As soon as the shear rate of the flow field increases 
beyond this threshold value, VWF multimers undergo large conformational changes to 
expose as many functional domains as possible to the bleeding site. In terms of 
elongation of VWF under high shear flow, the cutting edge studies show that the coiled-
globular shaped molecule can elongate to ten micrometers or more [5, 14, 15]. The VWF 
multimeric structure is initially stored in Weibel-Palade bodies (WPB) before the start of 
of hemostasis. Moreover, as reported in [13, 18], within 2 hours after release from WPB 
into the circulation, ultra-long VWF multimer is cleaved by ADAMTS13 (a disintegrin 
and metalloprotease with a thrombospondin type 1 motif, member 13) into smaller 
fragments with a wide range of size distributions. This process is repeated rapidly during 
the hemostasis process. Consequently, the length regulation of VWF is much more 
reasonable if it can be measured in post-secretion process [5].  
        As reported in [13, 18], within 2 hours after release from WPB into the circulation, 
ultra-long VWF multimer is cleaved by ADAMTS13 (a disintegrin and metalloprotease 
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with a thrombospondin type 1 motif, member 13) into smaller fragments with a wide 
range of size distributions. This process is repeated rapidly during the hemostasis process. 
While the VWF multimers are undergoing elongation, more binding sites are exposed to 
platelets. Thus the unfolding of VWF enables its maximum hemostatic function, i.e. 
immobilizes as many platelets as possible in a very short period of time. Moreover, 
stretched VWF multimers contact collagen in the sub-endothelial matrix at multiple 
binding sites to maintain firm platelet immobilization. The adhered vWF multimers 
eventually form a network to quickly capture platelets from the bleeding stream. Some 
researchers have determined the key role of multimeric VWF self-association or 
polymerization [19-21] in the formation of platelet plugs in hemostasis. Lots of studies 
have been conducted to understand the biochemistry of VWF- collagen adhesion. But a 
very limited number have looked at the adhesion strength (VWF-collagen and VWF- 
platelet). Therefore, characterizing the mechanical property of this ultra-long protein, 
especially the A-domains is an important task to understand the molecular mechanism of 
blood clotting especially under high shear flow during vessel injury.  
        Finally, the pathological VWF mutations from different types of VWD patients are 
of extraordinary importance to establish the function of different domains. Many mutant 
VWF proteins have been identified. For instance, a British team led by Dr. Thomas A. J. 
McKinnon has successfully matched different VWF pathology with defects in the A3 
domain[22] and the A2 domain [23]. Another group in Mayo Clinic reported an A1 
mutant VWF [24], which has what symptom? 
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3. Facilities and Devices  
3.1. Atomic Force Microscope (AFM) 
        Atomic force microscopy (AFM) is one type of scanning probe microscopy (SPM) 
with spatial resolution on the order of a fraction of a nanometer and force resolution 
down to single pico-Newton [25]. Nowadays, it is commonly implemented to measure 
biophysical properties biomolecules and bioparticles.  
 
 
Figure 3. a. Schematic of the homebuilt AFM. b. Typical AFM pulling curves using 
Titin I27. 
 
        A schematic diagram of the home-built atomic force microscope (AFM) used in this 
dissertation is shown in Figure 3a. The most important parts in this setup include a 
piezoelectric actuator, cantilever and photodiode detector. The piezoelectric effect is 
understood as the linear interaction between the mechanical and the electrical state in 
piezoelectric ceramic materials with no inversion symmetry [26]. In the home-built AFM, 
the piezoelectric ceramics exhibits a reverse piezoelectric effect: generation of a 
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mechanical strain from an applied electrical field. By controlling the voltage applied on 
the piezoelectric ceramic, a displacement of the probe can be achieved precisely. The 
setup used here has a displacement range of 15 micrometer and probe moving speed of 
0.4 micrometer/s to 40 micrometer/s.      
        As shown in Figure 3b, the pyramid-shaped tip repeatedly approaches, contacts and 
retracts from the substrate. Since the size of the tip is very small (Table 2 and 3), 
interaction between a single receptor−ligand pair [27] is achievable. A typical AFM force 
scanning curve i.e. voltage vs. piezoelectric actuator’s displacement is shown in Figure 
3b using four Titin I27. When the AFM cantilever tip contacts the Titin I27 immobilized 
on a gold-coated substrate, specific interactions occurs between Tintin I27 and the xxx 
functionalized tip. As the piezoelectric actuator retracts, the pulling force applied on the 
sample increases linearly due to the bending of cantilever.  
    
 
                     
Figure 4. a. AFM cantilevers. b. Schematic of an AFM cantilever tip. (Reprinted from 
Bruker website). 
 
 
B 
C 
D 
E
B 
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Table 2. Specification of AFM cantilever (Bruker). 
Shape 
  
Resonant Freq. (kHz) 
  
  
Spring Const. (N/m) 
  
  
Length (µm) 
  
  
Width (µm) 
  
Nom. Min Max. Nom. Min. Max. Nom. Min. Max. Nom. Min Max. 
A Triangular 22 15 30 0.07 0.025 0.14 175 170 180 22 17 27 
B Rectangular 15 10 20 0.02 0.005 0.04 210 205 215 20 15 25 
C Triangular 7 4 10 0.01 0.005 0.02 310 305 315 20 15 25 
D Triangular 15 10 20 0.03 0.01 0.06 225 220 230 20 15 25 
E Triangular 38 26 50 0.1 0.05 0.2 140 135 145 18 13 23 
F Triangular 125 90 160 0.6 0.3 1.2 85 80 90 18 13 23 
 
 
Table 3. Specification of AFM cantilever tips (Bruker). 
Geometry Rotated (Symmetric) 
Tip Height (h) 2.5 ~ 8.0µm 
Front Angle (FA) 15 ± 2.5º 
Back Angle (BA) 25 ± 2.5º 
Side Angle (SA) 17.5 ± 2.5º 
Tip Radius (Nom) 20 nm 
Tip Radius (Max) 60 nm 
Tip SetBack (TSB)(Nom) 4 µm 
Tip Set Back (TSB)(RNG) 0 ~ 7 µm 
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        The cantilevers used in this work are made of Silicon Nitride by the Bruker 
Company. By assembling a cantilever at the bottom of the piezoelectric actuator, it 
conducts the linear movement of the piezoelectric ceramic to the tips at its very front end. 
A photograph of three cantilevers is shown in Figure 4a, and one tip in Figure 4b. 
Detailed specification is summarized in Table 2 and 3. The cantilever can be moved with 
a sub-nanometer resolution in z-direction, which is conventionally perpendicular to the 
sample plane. During the controllable displacement of the cantilever, the tip repeats 
contact-retraction cycle on the objective samples on the stage. Consequently, the 
electrical signals are linearly converted to the displacement of the cantilever tips (passed 
down from the piezoelectric actuator). In this way, the indenting or pulling force is 
applied simultaneously. By following the displacement of piezoelectric actuator, the 
cantilever tip is driven to move in the resolution of sub-nanometer. Based on this 
mechanical setup, an optical system that includes a light source and a segmented 
photodiode detector, makes the data collection straightforward but accurate. The 
customized setup is specifically designed to conduct single molecule spectroscopy in 
biological samples. In the force-scanning mode [28, 29], a laser (wavelength = 655nm) is 
focused on the back of the cantilever tip. Due to the reflective gold coating, the laser is 
deflected and collected by a photodiode sensor via a controllable mirror. The optical 
signal is then transformed into electric current. The difference of the signal detected from 
the upper and lower quadrant of the photo detector monitors the deflection of the 
cantilever tip. Following Hooke's Law for small displacements, the interaction force 
between the tip and the sample is then determined from this signal after a proper 
calibration of the spring constant of the cantilever.  Taking the properties of the biological 
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sample into consideration, the contact-retraction loading cycle has to be set within 
physiological range. The tip of the cantilever can be functionalized with silane, polymer, 
protein ligands, etc. to establish specificity. For example, polylysine coated cantilever tip 
can capture cells or protein through electrostatic interaction, which can be further used to 
measure the interactions between cells or between biomolecules and cells. In this 
dissertation, proteins are covalently coupled to AFM cantilever tip to study the VWF-
ligand interactions.  
        The mechanical strength of ligand-receptor binding cannot be directly extrapolated 
from the binding affinities measured by conventional biochemical techniques. In fact, the 
force resistance can only be measured by specific force measuring techniques [30],  such 
as atomic force microscopy (AFM) [31], bio-membrane force probe [32], or transient 
tether measurements using flow chamber [33]. Among these, single molecule techniques 
such as optical tweezers and AFM are more informative because they define the 
molecular components of the reactions. In this dissertation, AFM is the main technique 
used to measure mechanical strength. 
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3.2. Miniature Optical Tweezers 
 
  
 
b 
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Figure 5. a. Optical tweezers. b. Fluidic setup of miniature optical tweezers. c. Optical 
layout of miniature optical tweezers (Reprinted from http://tweezerslab.unipr.it/cgi-
bin/mt/home.pl). 
 
        Devices for optically trapping small particles are better known as "optical traps" or 
"optical tweezers". Those optical tweezers apply one or more laser beams refracted by a 
microscopic object to trap, levitate and move the object. [34]. By focusing a laser beam 
though a microscope objective lens down to a very small spot (focal region), particles 
with high indices of refraction, such as glass, plastic, or oil droplets, are optically 
attracted to and permanently trapped at the beam's focal region (Figure 5b and c). From 
the perspective of biological applications, optical traps can achieve minute forces in sub-
piconewton (10-12) range. The miniature optical tweezers used in this dissertation, shown 
in Figure 5a, have two advantages over most other units: instead of calculating force 
based on spring constants and displacements, the miniature optical tweezers directly 
c 
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measures force without complicated calibration steps. Moreover, this device has a small 
size and is portable, compared to classic ones that require to be assembled on big optical 
tables. Additionally, the small size allows better isolation from surrounding noises and 
reduces optical interference. The main limitation of the miniature optical tweezers is that 
the force cannot exceed 100 piconewton (pN). Thus, for single molecular experiments 
that require relatively high loading, AFM is more applicable. On the other hand, the 
miniature optical tweezers are more accurate for small force measurements, e.g. the 
intramolecular and the intermolecular interaction between VWF and GPIbIX, which will 
be covered in later parts of this dissertation. 
 
3.3. Microfluidic Device 
 
 
 
 
 
 
Figure 6. Schematic of the homebuilt microfluidic device. b. Picture of the wafer used to 
make PDMS microfluidic devices. c. Device assembled on glass slide with inlet and 
outlet punched. 
a 
b
 
c 
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        Microfluidics are powerful research tools with a broad range of applications. Since 
their first demonstration in the 1950s, microfluidics has been applied in many disciplines, 
including physics, chemistry, biology, medical devices and medicine [35-38]. 
Microfluidic devices with characteristic dimensions on the micron scale can manipulate 
small volume of fluids with controllable flow fields. The main advantages can be 
summarized as follows: low reagent and sample volumes are needed, outstanding 
capability in parallel experiments, ability to mimic the physiology of the environment and 
pathological input, easy to isolate interesting factors of the objective procedure, ability to 
control local experimental parameters accurately and it has an extremely low cost. 
        Figure 6 shows the design of a microfluidic channel used in this work to achieve 
controllable hydrodynamic fields. The device has a spindle-like shape so molecules in the 
flow experience elongation, high shear and release in the three segments. This design 
simulates the elongational flow field occurs during bleeding. As a result, conformational 
changes of biopolymers and wall-effect interactions under laminar flow fields can be 
studied. The micro-channel is made of polydimethylsiloxane (PDMS) and bound with 
thin glass coverslips via an oxygen plasma treatment [39]. PDMS is optically clear, and, 
in general, inert, non-toxic, and non-flammable. This work focused on the high shear 
flow region in the middle, which provides a driving force for the conformational change. 
To achieve steady and continuous high shear rate flow in the channel, a Harvard syringe 
pump is utilized. Then flow rate of the pump setting can be figured out by simple 
calculation as following:  
                                                       H = V ∙ A = !!!! ∙ γ                                                     (1) 
 19 
Where V denotes the average velocity of flow, A denotes area of the cross-section, P 
denotes the wetted perimeter, and γ denotes the aimed shear rate. The internal surface of 
the channel is coated with functional layers depending on the flowing particles.   
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CHAPTER 2 
Biomechanical Characterization of VWF-collagen Interaction            
 1. Introduction 
        It has already been mentioned in the earlier chapter that to stop the bleeding from an 
injured blood vessel, a process known as coagulation forms the hemostatic plug to 
immediately stop bleeding at the damaged vessel wall. During this process, platelets that 
are circulating in the blood stream have been used as the main material of the plug. More 
importantly, the von Willebrand Factor (VWF) plays the most essential role by 
functioning as an injury locator, shear flow sensor [17] and platelet anchor [16]. The 
hemostatic plug formation starts with adhesion of blood platelets to perivascular 
connective tissue exposed at the damaged vascular wall through integrin-collagen 
interactions [40]. This rapid response is just an initial immobilization of platelets to locate 
the injured site and start the activation process. However, the bond in between is far from 
enough to resist the high shear flow induced by the damaged vessel. von Willebrand 
Factor (VWF) is  a natural solution for the human body, acting as the hero that firmly 
anchors onto the exposed collagen fiber with its A3 domain, and strengthens the 
immobilization of a platelet with its A1 domain [41, 42]. 
        Existing studies have shown that VWF is able to bind with collagen types III, IV, 
and I in the binding to the sub-endothelial matrix [43, 44]. The A3 domain (residues 923–
1109) of VWF serves as the main binding site of collagen [45].  However, some research 
groups have shown that the A1 domain binds types I and III collagen, though contrasting 
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evidence has been reported by other groups. [46, 47]. Therefore, does the A1 or A3 
domain of VWF bind with collagen solo, or do both of them bind together during the 
hemostasis process? This has been a long-lasting question in the field and will be further 
discussed in this chapter. From a larger scale, researchers have also conducted 
experiments in multimeric VWF to study the binding affinity to the collagen surface. A 
group led by Schneider has reported their result from a shear-induced stretching assay by 
using collagen coated microfluidic devices [17]. They further showed the formation of 
VWF network observed under flow conditions. 
        In a parallel manner, several remarkable theoretical studies have been done 
regarding the VWF-collagen interaction. In biochemistry, this type of interaction belongs 
to the reversible ligand-receptor-type bonds [48], which are very common in biological 
systems [49]. The typical way to deal with this kind of problem is utilizing the Bell 
model, which is a physical chemistry theory that claims the difference in activation 
energy between two reactions of the same family is proportional to the difference of their 
enthalpy of reaction [50-52]. As to simulating the VWF-collagen interaction, the Bell 
model has desirable capabilities that parameterize the energy landscape in a simplistic 
manner by clearly define each of the interacting entities as bound or unbound, and has 
included an energy term due to the externally applied force [51, 52]. Based on this theory, 
a so-called force spectroscopy methodology has been employed to quantify the 
biochemical bond over the past decade or so [53-55]. Narrowing down to the VWF-
collagen bond, the height of the energy barrier tells the transition rate between the 
association and disassociation state, e.g. greater height further impedes the bond and 
obstructs both the forward and backward transition while a smaller height shows a swift 
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binding-unbinding transition [48, 53]. At the same time, the width of the energy barrier 
between the two states describes by what degree the interaction can be influenced by 
external force, which will be discussed in later sections [50, 52].  
 
2. Materials and Methodology 
2.1. Samples and Materials 
        Within this chapter, an experiment is conducted to characterize the bond between 
different VWF and collagen. For the VWF here, the samples include: VWF monomer, 
VWF A3 domain, wild type VWF multimer, NEM- treated VWF multimer [23], 
W1745C mutant VWF multimer and S1783A mutant VWF multimer [22]. The detailed 
specification of the sample is summarized in Table 4.  
 
Table 4. Specification of the VWF samples.  
 
> 260 
> 260 
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        For the collagen substrate on the sample stage, the human placenta type I collagen 
from Sigma Aldrich has been used for the entire study. The product is reconditioned in 
water with acetic acid added to pH 3.0 to obtain a stock solution with the final 
concentration of 2mg/ml. The selected experimental buffer is Phosphate-buffered saline 
(PBS). The AFM cantilever is Bruker Nano’s MLCT-UT cantilever, and the glass slide to 
coat VWF is the common microscopy glass slide, 75 x 25 x 1 mm. It was cut into very 
small pieces before the coating step. Also, the amine-functionalized glass slide from 
NANOCS, 75 x 25 x 1 mm, is employed in the experiment too. Since this product has the 
amino group coated on the surface already, the coating process is partially simplified.     
 
2.2. Setup the Atomic Force Microscope (AFM) 
        The atomic force microscope (AFM) is employed as the experimental platform of 
this study. The reasons are as follows: first, the measurement is localized on the bond 
between single molecules; second, based on the flow experiment in [17], the desired 
force to disassociate VWF from collagen can be higher than 100 piconewton (pN), which 
> 260 
> 260 
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is the upper limit of optical tweezers’ measurement range; third, to make the force 
loading rate of unbinding comparable with the fluid dynamic loading in the flow 
experiment, the pulling  has to be maintained at a relatively high speed and the AFM 
performs well within this speed range.  
        Additionally, the energetic property of the VWF-collagen binding is another 
question expected to be answered. Consequently, the experiment should also be able to 
run at different temperatures. By taking this into the design of the unbinding assay, a 
temperature control component has been implemented in the homebuilt AFM device. As 
shown in Figure 7, the temperature control device used in this assay consisted of two 
Omega Engineering KHLV-0502 Kapton (polyimide film) insulated flexible heaters 
wired in parallel to a Volteq Hy3005D DC power supply and an Omega engineering 
HSTC series hermetically sealed, tip insulated, j-type thermocouple wired to a NI DAQ 
6215 which records the temperature data for the experiments. The two flexible heaters are 
adhered to a highly thermally resistant plastic microscope stage. Placed on top of the 
stage is the 35mm culture dish of which the flexible heaters are situated such that they are 
adjacent to two of the sides the dish. The thermocouple is allowed to touch the bottom of 
the dish and monitor its temperature. Note that the area of interest was considered to be 
small enough that there is not a significant temperature variation across its surface.  
         Furthermore, from the initial tests, the temperature across the surface can be shown 
by the thermocouple to at a relatively steady state during the experiment. The temperature 
is adjusted by varying the voltage from the power supply and waiting for a steady state to 
be reached on the bottom of the dish. Last, by taking the physiology factor into account, 
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the temperature should be limited within a certain range. Since this thermo device is not 
capable to decrease the temperature, the low end is at room temperature while the 
maximum is lower than 40o C for the most cases.  As shown in the schematic in Figure 7, 
the homebuilt AMF with the temperature control component is setup to run the unbinding 
assay on VWF-collagen interaction.  
 
 
Figure 7. Schematic of the homebuilt AFM with implementation of thermo control 
component. 
 
 2.3. Coating the Probes 
        Within this chapter, the most essential task is to measure the binding affinity 
between VWF and collagen. Thus it is essential that the single molecule measurement has 
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been localized on the binding sites of the two samples. To better achieve the single 
molecule condition, the most important preparation step is coating the objective proteins 
onto the probes. To implement the probe functionalization into the AFM, the two 
objective substrates are immobilized on the AFM cantilever tip and underneath the 
sample stage. Within this chapter, both sides are using the same coating methodology. In 
summary, there are three layers coated chronologically: (3-Aminopropyl)triethoxysilane 
(APTES), Acetal-PEG27-NHS and aiming ligand/protein/cell.  
 
    
Figure 8. Oxidation and gas phase APTES silanization of silicaon nitride tips 
 
        First, for the (3-Aminopropyl)triethoxysilane (APTES) coating layer, the so-called 
Gas Phase coating method (http://www.jku.at/biophysics/content) has been used to 
guarantee the quality of the amino-functionalization. AFM tips are mainly composed of 
silicon nitride (or silicon). They can be oxidized spontaneously in the ambient 
atmosphere, such that a thin layer of silicon dioxide is formed on the surface of the 
cantilever tips. The oxidation layer contains Si-OH group, which can be used for further 
chemical functionalization (see Figure 8). In the past, the rapid liquid phase amino-
silanization protocols were followed for this step. For this method, the APTES silane was 
simply buffered with polar solvents for example the Ethanol. Although the curing time of 
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the liquid-phase methods are as short as 15-20min, they are still inapplicable because 
long, sticky polymers are easily formed, which render AFM tips extremely sticky [56]. 
As to the application into the VWF- collagen unbinding experiment, a lot of nonspecific 
adhesion had been observed due to the inhomogeneous amino-silanization layer. 
Comparatively, the gas-phase amino-silanization allows depositing monomeric APTES 
molecules to form a homogeneous coating layer while avoiding the formation of large, 
sticky clusters [56, 57].  Figure 8 shows the entire conjugation process of the APTES 
silanization. The amino-functionalization steps are ordered from left to right. 
        The detailed protocol of using gas-phase amino-silanization to coat the AFM 
cantilever and glass slide is as the following (the original protocol is from 
http://www.jku.at/biophysics/content): 
1. Wash cantilevers (glass slides, cut in small piece) in chloroform for 5 min × 3 times. 
This step should be done in clean glass containers. Dry the cantilevers (glass slides) 
with nitrogen gas, continue with the next step. 
2. Flush desiccator chamber (5 L) with argon gas (through the narrow opening in the lid) 
for 5 min. 
3. Place two Eppendorf reaction vial lids in the desiccator, fill one with 30 µL fresh 
APTES and another one with 10 µL triethylamine under argon. 
4. Place the dried cantilevers (glass slides) in the desiccator close to the two reagents 
from step 4. Seal the desiccator, incubate for 2 h. 
 28 
5. Open the lid of the desiccator, remove the trays with APTES and triethylamine, flush 
desiccator with fresh argon for 5 min to remove the rest of gas-phase APTES. Incubate 
the cantilevers (glass slides) in argon for at least 48 hours to reinforce the coating.  
6. Preferably, the amino-functionalized cantilevers (glass slides) can be stored under 
argon in a dust box for one week. 
         Second, the second coating layer with the PEG linker (Acetal-PEG-NHS, from 
http://www.jku.at/biophysics/content) should be put on the amino-functionalized 
cantilevers (glass slides) as soon as possible. Although the APTES coating is supposed to 
be functional for one week, based on the practical experience, the best effect can be 
achieved if the PEG cross-linker is coated on right after the amino-functionalization. As 
shown in Figure 9, the PEG has two different arms on each end: NHS group and acetal 
group. When the PEG cross-linker contacts with the AFM cantilever tip in the solvents, 
the NHS group binds with amino group immediately. Furthermore, the acetal group can 
be converted into aldehyde group by immersing the entire cantilever (or glass slide, cut 
into small pieces) in 1% citric acid for 10 min. After that, the last step is the coupling of 
the protein and quenching the free aldehyde group [58]. 
 
 
 
 
 
Figure 9. Reaction of NHS-amino group that converts acetal into aldehyde. 
AFM Cantilever 
Tip Acetal group Aldehyde group 
 29 
        The detailed procedure to cross-link the amino-functionalized cantilevers (glass 
slides) with objective protein is conducted by following the protocol below (the original 
protocol is from http://www.jku.at/biophysics/content): 
1. Dissolve 1 mg of Acetal-PEG-NHS cross-linker in 0.5 ml chloroform, transfer the 
solution into the reaction chamber by using the scaled Hamilton glass syringe, add 
30µL trimethylamine, and mix well. 
2. Immediately immerse the amino-functionalized cantilevers (or glass slides) in the 
reaction chamber to react with the PEG, cover the chamber, and incubate for 2 h. 
3. Wash with chloroform for 10 min × 3 times. Dry with nitrogen gas. 
4. Up to this step, the acetal PEG coated cantilevers (glass slides) can be stored in 
desiccator under argon for up to several months. 
5. Soak PEG coated cantilevers (glass slides) in 1 % citric acid (in water) for 10min. 
6. Wash in water for 5 min × 3 times, then dry with nitrogen gas. After this step, the 
acetal has been converted to aldehyde that needs to link with objective protein 
immediately. 
7. Freshly prepare a 1 M solution of sodium cyanoborohydride (Sigma Aldrich). The 
recipe is: 13mg NaCNBH3 + 20µL 100mM NaOH + 180 µL DI water.  
8. Immerse the cantilevers (or glass slides) into 100 µL protein (e.g., VWF, VWF A3, 
Mutant VWF or collagen) solution with the concentration of 1-2 µM. With PBS, the 
VWF and collagen stock samples are diluted by 20 and 7 folds, respectively.  
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9. Add 2 µL of the 1 M sodium cyanoborohydride solution, pipette up and down 
carefully, seal with Parafilm, and incubate under room temperature for 1 h. 
10. Pipette 5 µL of ethanolamine (1 M, pH 8.0) to the coating solution (while the 
cantilevers and glass slides are still soaking in it), pipette up and down to mix well, 
seal with Parafilm and then incubate for 10 min. 
11. Wash in PBS or any other experimental buffer of choice for 5 min × 3 time. 
 
 
Figure 10. Schematic of the unbinding assay setup. The VWF-collagen unbinding assay 
is setup on AFM platform [59]. From the top to the bottom: AFM cantilever is mounted 
with the crystal holder that will perpendicularly drive the cantilever tip, the cantilever tip 
is coated with APTES in gas phase, acetal PEG crosslinker is conjugated to link the NHS 
with amino group, collagen is coated on the PEG layer after the acetal group is converted 
into aldehyde by 1% citric acid, VWF is coated with the same PEG on the functionalized 
glass piece, the VWF coated glass piece is placed in non-treated culture dish with PBS. 
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        Third, before the start of experiment, the functionalized cantilever is freshly 
mounted on the cantilever holder of the AFM. On the other side, the coated glass piece is 
placed in a non-treated petri dish, which was fixed on the sample stage perpendicularly 
under the cantilever. The entire setup of the VWF-collagen unbinding assay is illustrated 
as in Figure 10 above.  
        There is one challenge throughout the experiment: how to guarantee that a 
measurement is conducted between single molecules. There is a criterion that has been 
used a lot for single molecule study. Based on one statistic calculation, when the 
percentage of specific adhesion is roughly about 30%, people believe the assays are under 
single molecule situation. This particular detail will be discussed later, but the method of 
preparing the experiment to achieve single molecule measurement should be solved 
during the setup stage of the experiments. The easy but effective way to do it is adjusting 
the sample density on both the probe and substrate. After several preliminary trials 
regarding the ratio of the coating density, the optimal concentration for collagen and 
VWF has been determined, which are listed in the previous protocol above.  
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3. Results and Discussion 
3.1. Experimentally Measure the Rupture Force and loading Rate for Dynamic 
Force Spectrum 
        The first measurement was conducted on the VWF monomer-collagen and the VWF 
A3 domain-collagen. Although it has been reported that the A3 domain is the major 
binding site for collagen [60], some other researches claim that A1 domain binds with 
collagen as well [46, 47]. The adhesive interaction between VWF and collagen maintains 
the immobilization of VWF that further assist platelets to rapidly attach to the injured 
vessel wall in the blood flow stream. As mentioned before, VWF experiences significant 
hydrodynamic forces in circulation within the human body when hemorrhage occurs in 
the vessels. Therefore, it is very important to understand the mechanisms that enable 
adhesion bonds to resist the shear forces in the vasculature.  
        As introduced earlier, by applying the piezoelectric actuator, the AFM cantilever 
conducts controllable “touch” between VWF and collagen. The entire movement contains 
two parts: approaching and retraction. The cantilever moves perpendicularly at a preset 
speed, and then approaches the collagen substrate on the sample stage. When the two 
proteins contact each other, the piezoelectric actuator continues applying indentation until 
the force reaches the preset threshold value that prevents the cantilever from penetrating 
the substrate. Also, the “dwell time” (i.e., contact time) is set initially by the software to 
make sure VWF and collagen fully interact with each other. The preset parameters for 
trails are listed in Table 5 below. The experiments were conducted between VWF 
monomer and collagen, VWF A3 domain and collagen. The scanning range determines 
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the perpendicular distance that the cantilever moves without touching anything. For 
instance, if the VWF coated slide is 10 µm from the original point of the cantilever, the 
piezoelectric will move 10 µm down until it touches with the slide. The indentation force 
will then increase until the threshold. At this moment, the approaching ends and the 
retraction starts after the dwell time passes. The time between scans is the gap period that 
separates each scan allowing the sample to relax enough for the next cycle.         
 
Table 5. Preset parameters of the AFM 
 
 
        For each force scanning cycle, the Igor software records one pulling curve, which is 
plotted with all the data points collected during the entire scanning process. In Figure 11, 
some typical pulling curves are shown. For each force-scanning curve, the X-axis is the 
displacement of the cantilever in µm, and the Y-axis is the different signal (A-B), which 
is proportional to the force being applied on the sample. The positive voltage shows the 
Preset Parameter Values for Different Trails 
Samples VWF monomer/VWF A3 vs. Collagen 
Pulling speed (µm/s) 0.75, 1.50, 3.13, 6.27, 9.40 
Scanning range (µm) 0~15 
Indentation Threshold (mV) < 200 
Dwell time (s) 0, 1/6, 1/3, 1/2 
Time between scans (s) 2 
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force loading is pulling, conversely, the negative voltage means indenting. By matching 
the resultant curve with the approaching-retraction cycle of the force-scanning mode of 
AFM, Figure 11 describes the process as follows: First, the collagen coated cantilever 
starts moving down to approach the VWF coated glass slide on the bottom. This stage is 
illustrated by the blue (lower) curve in the direction marked by the blue arrow. Second, 
after the cantilever touches the collagen substrate, the tip is bent immediately and its 
deflection signal increases negatively. The sudden drop of the blue curve near the y-axis 
shows this stage. Third, after the controllable indentation is kept for the dwell time, the 
collagen coated cantilever starts retraction from the contacting stage. The recovery part of 
the red curve that overlaps with the blue drop records the retraction. At this point, if there 
is any adhesion between the samples, the retraction curve will track a positive peak as 
shown in the left ones of Figure 11. Finally, along with the retraction of the cantilever, 
the pulling force keeps increasing so that the bond between the samples ruptures when 
the adhesive affinity breaks. The bended cantilever tip then springs back after released. 
By showing on the plot, the retraction curve (red) falls back to the zero line. One of the 
most essential parameters that determine the dynamic force spectrum of a biochemical 
bond is the rupture force of the retraction during each force scan. Those adhesion peaks 
not only show the magnitude of the pulling force at the moment when the specific bond 
breaks but they also reflect the force loading rate with the value of the local slope. One of 
the adhesion peaks is zoomed in and shown in Figure 11. As marked in the figure, the 
adhesion peak in the pulling curve slants up to achieve the maximum pulling force, and 
then ruptures and drops back to the standard line. After calibration (measure the spring 
constant and the voltage-force ratio of the cantilever tip), the Y-direction height of the 
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peak can be converted to the magnitude of the rupture force, and the fitted slope will be 
used to calculate the individual force loading rate. The raw data is then collected by 
recording the y-direction height and the local slope for each adhesion peak.      
 
 
 
 
Figure 11. Typical Pulling curves plotted by Igor software (Blue: approaching, Red: 
retraction). Left: force scans with adhesion between samples. Right: force scans without 
adhesion between samples.  
 
 
Approaching 
Retraction Rupture 
Force 
Fitted 
Slope 
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3.2. Adhesion Percentage and Control Group 
        Up until this step, it has not been clear whether the interactions measured by this 
experiment stem from the specific binding between VWF and collagen. There are two 
possibilities of non-specific interactions: first, the acetal PEG may not be fully converted 
into aldehyde, but will it bind with the substrate underneath? Second, by using the 
ethanolamine (1 M, pH 8.0) to quench the free aldehyde group in the very last step of the 
coating, all the aldehyde-amino binding sites are blocked for sure, but will the 
ethanolamine quenched aldehyde still interact with the substrate on the other side of the 
assay? To exclude these two possibilities, control experiments have to be carefully 
conducted. As shown in Figure 12, from left to right, bar one to five represent the 
adhesion percentage of each experimental control group, six and seven represents the two 
adhesion percentage of the experiments of VWF monomer-collagen and A3 domain-
collagen. Before mounted on AFM, every pair was quenched by ethanolamine to 
eliminate free aldehyde sites. The three control experiments are: (1) Control-PEG vs. 
VWF, (2) Control-Collagen vs. PEG, (3) Control-PEG vs. PEG. After that, from bar 4, 
each one presents the adhesion percentage of different sample pair: (4) Collagen vs. VWF 
monomer, (5) Collagen vs. VWF A3 domain, (6) Collagen vs. WT VWF multimer, (7) 
Collagen vs. NEW treated VWF multimer, (8) Collagen vs. S1731T mutation, (9) 
Collagen vs. VWF A1 domain and (10) Collagen vs. W1745C mutation. The result 
clearly shows condition six and seven are of a higher percentage of adhesion and it 
roughly agrees with the single molecule criterion. The specification of the VWF- 
collagen unbinding assay is confirmed. More importantly, the experiment on Collagen vs. 
VWF A1 domain here serves as an essential evidence to prove that the A1 domain is not 
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a binding site of collagen Type I. As reported in existing literature [61-63], VWF A1 
domain binds with collagen Type IV. However, there is still no result on the adhesion 
between collagen type I and VWF A1 domain. This point is actually very beneficial to 
our study. Since the interference of A1-collagen interaction can be excluded throughout 
the entire experimental trial, the study was then focused on the collagen-A3 binding. 
 
 
Figure 12. Control experiment group. Every one is quenched with ethanolamine. 
Adhesion percentage: (1) Control-PEG vs. VWF, (2) Control-Collagen vs. PEG, (3) 
Control-PEG vs. PEG, (4) Collagen vs. VWF monomer, (5) Collagen vs, VWF A3 
domain, (6) Collagen vs. WT VWF multimer, (7) Collagen vs. NEW treated VWF 
multimer, (8) Collagen vs. S1731T mutation, (9) Collagen vs. VWF A1 domain and (10) 
Collagen vs. W1745C mutation. 
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3.3. Identify The Most Probable Rupture Force Under Each Pulling Speed. 
 
 
Figure 13. Histograms of the rupture force for VWF monomer-collagen unbinding. X-
axis is the magnitude of rupture force with unit of pN. Y-axis is the probability of event 
under certain rupture force range. Five pulling speeds distribute from 1.04 um/s to 9.38 
um/s. 
 
        Equivalently, for each sample pair, the unbinding assay is run at different pulling 
speeds as a trail. While different loading rates are applied, the rupture force varies 
dependently. Particularly, the experiment on VWF monomer – collagen has been done at 
five pulling speeds (can be easily convert to loading rate by multiplying spring constant). 
Recall the Bell- Evans model for plotting the dynamic force spectrum, the very first step 
is to post-process the raw data to find out the most probable rupture force under each 
pulling speed. To do that, a statistical analysis is employed here on the raw data. The 
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histograms (probability) of the rupture force at different pulling speeds are shown in 
Figure 13.  
        The same measurement scenarios have also been conducted on VWF A3 domain-
collagen interaction, which is shown in Figure 14. For this sample pair, the experiment 
has been run under four different pulling speeds that are comparable with VWF 
monomer-collagen unbinding assay. 
 
 
Figure 14. Histograms of the rupture force for VWF A3 domain-collagen unbinding. X-
axis is the magnitude of rupture force with unit of pN. Y-axis is the probability of event 
under certain rupture force range. Four pulling speeds distribute from 1.04 um/s to 9.38 
um/s. 
 
        From the histograms in Figure 13 and 14, it is very clear that the most probable 
rupture force is increasing along with the pulling speed. Each pulling speed (µm/s) is then 
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converted to the force loading rate (pN/s) by multiplying it with the calibrated spring 
constant of the AFM cantilever tip. After that, the dynamic force spectrum was plotted as 
the most probable rupture force versus the force loading rate. The data fitting process will 
be discussed in the next section. 
 
3.4. Fitting Data with The Bell- Evans Model  
        The dynamic force spectrum is specifically developed to analyze the properties of 
adhesive bond in biochemistry, chemistry and physics fields. Biochemistry scientists 
have been working on those kinds of theoretical models for several decades. In 1978, Bell 
proposed his work and later modified by Evans and other researchers [50, 52]. The Bell 
model is built by utilizing the transition state theory. As shown in equation (2) below, the 
formula describes how the influence of an external force can exponentially change the 
rate of bond dissociation: 
                                           
(2) 
Where f is external force in the unit of N, k0 is the dissociation rate constant obtained in 
the absence of the applied force, T is absolute temperature in the unit of Kelvin, kB is 
Boltzmann's constant: 1.3806488 × 10-23 m2 kg s-2 K-1 and γ is the energetic barrier 
distance between the bond state and the transition state along the reaction coordinate. 
Consequently, the Bell model describes that the dissociation rate of the adhesive bond 
increases exponentially to an external pulling force. Although there is no precise 
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theoretical justification for the correctness of exponential relation proposed by Bell, 
recent experimental studies have shown support and general acceptance of this model 
[53, 54, 64]. The two parameters k0 (disassociation rate constant) and Δx (barrier 
distance) are the two key parameters calculated by Bell model. In chemical theory, they 
describe the depth and the width of the potential barrier, respectively. Based on this 
understanding, the energy potential of the protein−ligand bond can be accurately defined 
by the force spectrum. Furthermore, in biomechanics, the Δx value is even more 
important than others, because it indicates the force resistance of an adhesive bond. To 
better explain, if the γ value of the protein−ligand bond is small, the external force will 
have the minimum influence on the bonds’ off rate koff (f) under certain external force f, 
due to the multiplication of f and Δx is small. Conversely, if the Δx value of the 
protein−ligand bond is large, then the binding will be very sensitive to external force. 
Again, the reason is the multiplication f∙Δx term becomes much larger here, which 
increases the activation potential respectively. Therefore, the parameter γ has also been 
referred to as the “mechanical strength” of a receptor−ligand bond. However, the value γ 
is not directly related to the change of the net free energy, thus it cannot be directly 
extrapolated from the binding affinities. 
        Originally, the Bell model is utilized to govern how the bond dissociation is effected 
by the constant pulling forces. However, with the setup of the AFM, pulling the sample 
pair with a constant force is hard to achieve experimentally. Under this circumstance, 
running the unbinding assay in linearly increasing force is more feasible by simply 
applying a constant pulling speed on the experimental probe. In 1997, Evans and 
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colleagues then modified Bell model to expand its capability that can handle the case of 
linearly increasing force. While the pulling force is increasing linearly, the most probable 
force f*, can be expressed as a function of the loading rate rf (rf =df/dt): 
                                   (3) 
This developed model is called Bell-Evans model (Equation 3). It shows that the most 
probable unbinding force f* (rupture force) has a linear relationship with the natural 
logarithm of rf. Experimentally, the most probable unbinding force f* (rupture force) is 
obtained from its histogram as elaborated earlier. From the plot of f* versus ln (rf), the 
Bell model parameters can be obtained from the slope and the y-intercept of the linear fit.  
 
The plot of f* vs. ln(rf) was then named “Dynamic Force Spectrum” [50]. By fitting with 
the Bell-Evans model, the dynamic force spectrum of VWF monomer-collagen and VWF 
A3 domain-collagen with the Bell model parameters are plotted and shown in Figure 15. 
Respectively, these two adhesive bonds are very similar to each other. From the single 
molecule AFM experiment, the strength of VWF monomer-collagen and VWF A3 
domain-collagen bonds has been measured. Also, from the similarity between the two 
sample pairs on the force spectrum, it can be confirmed that, at least with the 
recombinant proteins samples tested, the A3 domain within VWF is the dominant binding 
site of collagen. 
 
                             (4) 
 
                             (5) 
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Figure 15. Dynamic force spectrum of VWF monomer-collagen and VWF A3 domain-
collagen with fitted Bell model parameters. 
 
        In human plasma, VWF exists in a multimeric form, composed of up to 200 
monomers. VWF multimers can reach a molecular weight of 2×106 Daltons and a length 
of up to 100 µm when stretched [4]. With such enormous length, multimeric VWF carries 
many binding sites for platelets and collagen and suffers highly significant hydrodynamic 
forces in the circulating system. When large multimeric VWF circulates in the 
vasculature, the force applied to stretch the VWF has been estimated to be tens of pico-
Newtons. Our data indicate that one to a few A3-collagen bonds would be able to resist 
the force imposed by the blood flow. This allows the VWF to anchor on the collagen-
exposed vessel wall and allows sufficient time for the VWF to elongate on the surface, 
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which further exposes more A3 to attach VWF. Consistently, in vivo experiments have 
indicated that efficient VWF binding to collagen is highly dependent on the presence of 
VWF multimers of high or ultrahigh molecular weight. 
        VWF binds to collagen at 2 sites: the A3 domain (residues 1683-1874) contains the 
main site for fibrillar types I and III collagen found within perivascular connective tissue, 
and the A1 domain (residues 1260-1471) binds non-fibrillar type VI collagen within the 
subendothelial matrix. However, some research groups have shown that the A1 domain 
binds types I and III collagen, though contrasting evidence has been reported by other 
groups. In this study, using an A1 domain that has been shown to bind platelet GPIb-IX, 
we did not observe any specific A1-collagen binding. It is conceivable, however, that the 
unbinding force between A1 and collagen was too weak to be detected using our AFM, 
which has detection limit of 20 pN. 
        Upon tissue damage, the A3 domain first anchors the VWF onto subendothelial 
collagen. Subsequently, the A1 domain, via its engagement with GPIB-IX, captures 
platelets from the flowing blood. When both A3 and A1 bind their ligands, significant 
tensile forces develop along the bonded chain consisting of GPIbα, A1-A2-A3 and 
collagen. The mechanical properties of A1-GPIbα and A3-collagen interactions dictate 
the lifetime of the bonded chain. Fig. 4 shows a comparison of the mechanical properties 
of the A1-GPIbα and A3-collagen interactions. An examination of the kinetic lifetime 
profiles revealed that when the force was lower than 20 pN, the A1-GPIbα bond is 
stronger than the A3-collagen bond. However, for higher forces, the A3-collagen bond is 
stronger, which is consistent with the notion that VWF is only indispensable under high 
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shear, which leads to the application of larger forces on the bonded chain. In contrast, in 
lower shear or static conditions, platelets can adhere to collagen via the integrin receptor 
α2β1.  
 
 
Figure 16. Comparison of bond lifetime as a function of the force of A3-collagen 
interactions, A1-GPIbα interactions and A2 unfolding. The force-dependent lifetimes 
(1/dissociation rate) of the complexes were determined by the Bell model parameters, 
shown in Figure 15, or from literature.  
 
        The A2 domain, a mechanosensor located between A1 and A3, can be unfolded and 
cleaved by enzymes to prevent excessive platelet aggregation. The tension developed 
along the bonded chain may unfold the A2. A comparison of the lifetimes of the A3-
collagen interaction and A2 unfolding (Figure 16) revealed that the A2 lifetime is longer 
than the A3-collagen interaction when the force is less than 10 pN. Therefore, for pulling 
forces less than 10 pN, A2 remains folded. However, when the force is greater than 10 
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pN, the lifetime of the A3-collagen interaction becomes longer than the folded A2, 
suggesting that A2 is unfolded under high forces before the bonded chain detaches. This 
unfolding may allow A2 cleavage to take place to prevent platelet aggregation. 
        In general, the unbinding assay on AFM platform is a very successful 
implementation of mechanical methodology into biological study. Probing the 
mechanical and energetic properties of the bioaffinity with single-molecule method, not 
only provides a novel quantitative tool to detect the biological interactions, but also 
uncover the most essential mechanical properties of the interactions. The goal of this 
work was to establish a more in depth understanding of the biomechanical properties that 
defines the binding between the A3 domain of VWF and collagen. Our data indicate that 
the three WT constructs, A3, VWF monomers and VWF multimers, unbind with type I 
collagen in a similar fashion. Under loading rates of 800 to 20,000 pN/s, the unbinding 
forces of all three constructs ranged from 50 to 110 pN. The range of loading rates was 
picked based on the fact that earlier work has demonstrated this to be physiologically 
relevant to in vivo conditions [17, 65, 66]. Under the assumption that platelets behave as 
spherical beads with the radius of 1 µm, it can be estimated that at 20 dyn/cm2, a typical 
shear stress found in the microvasculature, the calculated drag force exerted on a single 
platelet is 64 pN. Therefore, the range of unbinding forces matches the force that VWF 
potentially receives from a platelet, indicating that one or a few A3-collagen bonds would 
be able to resist the force imposed by a platelet in blood flow. 
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3.5.  Utilize AFM Unbinding Assay to Define The Force Spectrum for Mutant VWF 
Multimers 
 
 
Figure 17. Ribbon diagram of the VWF with mutant A3 domain. The putative collagen-
binding surface is toward the lower left of the A3 domain in this view. The 3 naturally 
mutated residues are shown as blue sticks. H1786 is shown as a yellow stick [22]. 
      
        As reported in [16, 45], A3 domain binds the fibrillar collagen type I and III, both 
found in perivascular connective tissue (sub-endothelial matrix). Generally, there are 
various loss-of-function mutations in the A3 domain, which weaken the VWF-collagen 
binding. In a recent report published in Blood [22], researchers have studied three 
mutations: W1745C, S1783A and S1731T which were found in patients with VWD 
symptoms. By utilizing ELISA type collagen biding assay, W1745C and S1783A were 
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found to largely abolish VWF-collagen binding, and S1731T weaken binding by roughly 
50 percent. Moreover, the group tested another artificial mutation called H1786A, which 
completely eliminates collagen binding. The locations of the mentioned mutations in A3 
domain are marked in Figure 17.  Therefore, to obtain a comprehensive understanding on 
the mechanism of the VWF-collagen interaction, also to connect this study with the 
pathologic deficiency from clinical observation, the AFM unbinding assay has been run 
on various loss-of-function mutations in the A3 domain. In this way, the molecular 
determinants that dictate the mechanical strength of A3-collagen complex will be 
identified as well. 
        The experimental procedure was very similar as in the experiments discussed earlier 
in this chapter. After the AFM unbinding assay measurement, the result of different 
sample pairs was again fitted with Bell-Evans model to obtain the dynamic force 
spectrum and further predict the potential barrier parameters. By comparing their Bell 
model parameters, we can finally determine how these mutations alter the force 
resistance of the A3-collagen affinity within the molecule. Furthermore, we compare the 
resultant force spectrum (mutants) with previously reported VWF-collagen data from 
biochemistry assays to help understand the abolishment and establish close connection 
between the in vitro experiments and clinical observations. 
        We began with the wild type VWF multimer. Again, the AFM cantilever and the 
glass slide were amino-functionalized with the gas phase APTES, and then coupled with 
acetal PEG. Lastly, the cantilever is coated with collagen and the glass piece with WT 
VWF. After mounting the samples into AFM, the unbinding assay is conducted in five 
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pulling speed that are the same as we did for VWF monomer and A3 domain. The force 
spectrum of WT VWF is shown in Figure 18 together with VWF monomer and A3 
domain.  
 
 
Figure 18. Dynamic force spectrum of WT VWF-collagen interactions, including WT 
VWF multimer, VWF monomer and VWF A3 domain. 
     
 
        As shown in the plot of Figure 18, the blue line (WT VWF multimer) is almost 
overlapped with the red line (A3 domain) and black line (WT VWF monomer). Also, the 
resultant k0 and ΔX are very similar for each case. Therefore, when we pull the WT VWF 
multimer, the A3 domains on it are still undergoing the unbinding assay with collagen. 
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The result further proves the A3 domain is the dominant binding site within VWF. We 
have zoomed out from single domain scale to the multimeric scale of VWF. Moreover, 
this experiment serves as a linkage of the entire trail, because the mutant VWF samples 
that will be examined later are multimers. Based on the result of WT VWF multimer, the 
binding affinity between mutations and collagen will be characterized quantitatively.  
Another important but obscure issue is VWF’s free thiols. Thiol (sulfhydryl) groups on 
two cysteine residues may form disulfide bonds. Disulfides are in general very important 
in supporting protein folding, stability and function. The VWF molecule is very rich in 
cysteines. 8% of matured VWF’s 2050 amino acids are csysteins, compared with only 
2% cysteines normally existed in human proteins. It has been suggested that mature VWF 
contains about 80 pairs of disulfide bonds.  However, recent studies show that after 
secretion, the disulfides within VWF can be broken by a few potential mechanisms, such 
as the presence of reducing agent or enzymes in the circulation or culture media, the 
exposure of VWF to high shear stress, and the lack of N-linked glycans. Disulfide 
reduction leads to free thiols present on VWF. How these free thiols affect VWF’s 
structure and function is not well understood.  
        In this study, multimeric VWF was first mildly reduced by physiologically relevant, 
submicromolar concentration of reducing agents. The reduced VWF was then treated 
with N-ethylmaleimide (NEM) to prevent the formation of disulfides among the free 
thiols. The NEM treated VWF (NEM-VWF), was coupled to glass surface for AFM 
unbinding assay. As shown in Figure 19, DFS revealed that NEM treatment yielded 
significantly lower unbinding forces between VWF and collagen. Fitting the DFS to the 
single-barrier Bell-Evans model yielded 3-fold increase of dissociation rate after NEM 
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treatment. Therefore, the result suggests the presence of free thiols decreases the 
mechanical strength between VWF and collagen. The underlying mechanism behind this 
decrease warrants a further exploration.    
 
Figure 19. Dynamic force spectrum of NEM treated VWF-collagen interaction, 
comparing with WT VWF multimer. 
 
        At this point, we have obtained the force spectrum of NEM treated VWF multimer. 
Lastly, the unbinding assay is again conducted on the VWF pathological mutations: 
S1731T and W1745C. The force spectrum is shown in Figure 20 with WT VWF 
multimer as the comparison. It has been reported in [22], the S1731T mutation abolished 
the A3-collagen binding by about half and W1745C doesn’t interact with collagen type I, 
proved by the ELISA binding assay in Figure 21. In the resultant force spectrum of 
WT	  multimer	  
K
0
	  =	  4.066S
-­‐1
	  
∆X	  =	  0.199nm 
NEM	  multimer	  
K
0
	  =	  8.748	  S
-­‐1
	  
∆X	  =	  0.238nm 
 52 
S1731T mutation, the dissociation rate k0 is 2-fold greater than that of WT multiemr, 
which agrees with the result of VWF-colalgen ELISA binding assay. As to the W1745C 
mutation, recalling the adhesion percentage in Figure 12, it almost has no adhesive 
affinity with collagen, which agrees with the ELISA result as well.  
 
 
Figure 20. Dynamic force spectrum of S1731T VWF mutation (green) and W1745C 
VWF mutation (orange), comparing with WT VWF multimer (blue). 
  
WT	  multimer	  
K
0
	  =	  4.066	  S
-­‐1
	  
∆X	  =	  0.199	  nm S1731T	  mutation	  
K
0
	  =	  8.858	  S
-­‐1
	  
∆X	  =	  0.243	  nm 
W1745C	  mutation	  
No binding 
 53 
 
Figure 21. Type I collagen with VWF: Ag ELISA. Error bars represent mean ±SD of 3 
separate experiments performed in duplicate [22]. 
 
        Functional defects in VWF result in VWD, the most common hereditary bleeding 
disorder affecting approximately 1% of the population. Type 2M VWD is caused by 
mutations in A1 or A3 domains that lead to decreased binding of VWF to platelets or 
collagen. To examine if a change in the overall unbinding force could be correlated to 
structural mutations found in 2M VWD, unbinding experiments were performed on two 
VWD A3 domain mutants, S1731T and W1745C. Clinically, S1731T is associated with 
mild bleeding, and W1745C induces moderate to severe bleeding. Previous ELISA-type 
collagen binding assays indicated that W1745C VWF does not bind to both type I and III 
collagen, and S1731T induces only a reduction in binding to type I collagen. In our AFM 
assay, we did not observe any specific binding between W1745C VWF and collagen. 
S1731T VWF exhibited specific but significantly decreased unbinding force on collagen. 
Bell model analysis suggested that S1731T mutation did not change the width of the 
activation barrier, but suppressed the height of the barrier by 1.1 kBT. Our result is 
consistent with clinical observations and the previous collagen binding assay. Moreover, 
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the data demonstrates that after further optimization and validation using human serum 
samples, the AFM assay could potentially become a very useful tool used to identify 
future unknown type 2M VWD mutations.  
 
4. Conclusion 
         In this chapter, unbinding assays on the AFM platform have been carefully 
conducted. The first experiment was executed to compare the dynamic force spectrum of 
VWF monomer-collagen with VWF A3 domain-collagen. An overall force spectrum has 
been plotted to summarize the result of each sample pair as in Figure 22 and the Bell 
model parameters are listed in Table 6. The result agrees with the initial hypothesis. We 
have confirmed that: first, A3 domain is the dominant binding site of collagen Type I 
within VWF; second, the A1 domain doesn’t have obvious interactions with collagen; 
third, the adhesive bond between single VWF A3 domain-collagen is medium (roughly 
100 pN level), but still not enough to resist extremely high shear flow during hemostasis 
process. The conclusions from this chapter also explain why the VWF are always in 
multimeric structure and the formation of the VWF network in a healthy blood 
circulating system. Moreover, our data suggest that the VWF-collagen interaction is 
particularly suitable for mediating platelet-collagen interactions under high shear 
conditions. VWD A3 mutations alter the mechanical properties of the interaction, 
resulting in weaker unbinding forces and lower activation barriers. The VWF-collagen 
interaction also supports A2 unfolding to suppress excessive platelet adhesion. The single 
molecule experiment on the AFM platform is a reliable and rapid assay methodology to 
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characterize the bio-interactions between molecules. It supplies biologists a totally new 
angle to look at the biological system both functionally and structurally. It is noteworthy 
that the single-barrier Bell-Evans model is the simplest model to interpret our 
experimental data. The data may also be interpreted by several other models, or by the 
multiple barrier Bell-Evans model. 
 
 
Figure 22. Dynamic force spectrum of all the sample pairs: WT multimer vs. collagen 
(blue), A3 domain vs. collagen (red), WT monomer vs. collagen (black), NEW treated 
VWF vs. collagen (pink), S1731T VWF mutation vs. collagen (green) and W1745C 
VWF mutation vs. collagen (orange). 
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Table 6. Summary of The Bell Model Parameters for Each Sample in The 
Unbinding Assay. 
 
Sample  K0 (s-1) ∆X  (nm) 
A3 3.016 0.239 
Monomer 2.928 0.271 
WT multimer 4.06591 0.199035 
NEM multimer 8.74785 0.23816 
S1731T mutation 8.85773 0.24346 
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CHAPTER 3 
Identification of a Juxtamembrane Mechanosensitive Domain in 
the Platelet Mechanosensor Glycoprotein Ib-IX Complex 
1. Introduction 
        Physiological hemostasis is an important vascular functionality that enables the 
blood circulation system to rapidly fix the vessel injury. Throughout the thrombosis 
process, von Willebrand factor (vWF) and platelets play the most essential roles to 
mediate healthy hemostasis from pathological thrombosis [68]. Chapter 2 discussed that 
vWF assists the platelet to localize and immobilize on the damaged part of the vessel 
wall. On the other hand, the platelet performs aggregation due to the stimulation from 
vWF. During platelet aggregation, the glycoproteins (GP)Ib-IX and GPIIb-IIIa are the 
main receptor complexes that process the stimulating signals on the platelet membrane 
[5, 69, 70].  When vWF is bridging over the collagen and platelet during high shear in the 
blood stream, it opens up the conformational structure to expose as many functional 
domains as possible [13, 71, 72].  In the same time, the platelet aggregates to form 
filopodia, which tremendously increases the contact area of platelet (via a self-association 
function) [73]. A lot of existing studies have reported that the stimulating signal is 
transmitted by a subunit of GPIb-IX complex: GPIbα [74-76]. However, how this 
receptor complex processes the fluid dynamical signal and transforms it into a biological 
stimulation to mediate platelet functionality remains unknown. 
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        The GPIb-IX complex is structured with GPIbα, GPIbβ, and GPIX subunits in a 
1:2:1 ratio [77]. Within the complex, the binding site of von Willebrand Factor (vWF) A1 
domain, which is a leucine-rich repeat domain, is located in the GPIbα N-terminal.  The 
A1crystal structures have been determined by [78] and shown below in Figure 23.  The 
exact identification of the bond between vWF A1 domain and GPIb IX is still contentious 
in existing literature [79, 80].  
 
 
Figure 23. Ribbon structures of the VWF-GPIb-IX complex binding [78]. 
 
        To identify the mechanosensitive mechanism of the GPIb-IX complex, collaborating 
with Dr. Renhao Li’s group, we employ the optical tweezers pulling assay on VWF A1 
domain-GPIb-IX complex [76]. This is the first single-molecule experiment on the full-
length recombinant GPIb-IX complex. Specifically, the GPIb-IX complex and 
recombinant vWF A1 domain (or vWF monomer) are coated on different beads, and then 
pulled by the optical-tweezers. Since the optical tweezers platform has very good 
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resolution (sub-picoNewton and nanometer levels), the unfolding of the juxtamembrane 
stalk region of GPIbα is expected before the dissociation of vWF A1 domain from the 
GPIb-IX complex. Also, the unbinding phenomenon can be measured after the unfolding 
as well.         
        Under healthy physiological conditions, the hemostatic plug is not formed in blood 
circulating system until the vascular damage happens. However the adhesive interaction 
can be externally changed by botrocetin, a component of Bothrops jararaca venom [81].  
It has been reported that the botrocetin promotes the binding affinity between VWF A1 
domain and the GPIb-IX complex on the platelet even when flow field is of relatively 
low shear. This external enhancement is pathological, because the undesirable interaction 
causes the loss of effective VWF multimers and a quench of circulating platelets [82, 83]. 
One hypothesis is the botrocetin first forms a tight binary complex with the VWF A1 
domain to enhance its interaction with inactivated GPIbα [84]. Some other researchers 
also claim that the botrocetin enhances VWF A1 domain-GPIbα interaction by inserting 
an additional binding surface [85]. However, the mechanism of this external 
enhancement, by which the botrocetin is able to strengthen the binding between VWF 
and GPIb-IX complex, is still mysterious in the field.  
        Building on the platform of optical-tweezers, we are able to physically measure the 
enhancement from botrocetin throughout the interaction between VWF and GPIb-IX 
complex by introducing new fluid environment that contains botrocetin. Under this 
circumstance, the underlying VWF-GPIb-IX interaction is immediately placed under the 
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influence of botrocetin. A comparison then can be easily established to determine the 
enhancement of bothocetin in a kinetic phase.   
 
2. Materials and Methodology 
2.1. Biotinylated GPIb-IX complex 
        As described in [76], HEK293 Tet-on cells were co-transfected by plasmids 
pBIG5b-BirA/Ibb/EGFP and pUC19-puro using Lipofectamine 2000 (Invitrogen). The 
pUC19-puro plasmid was generated by ligating the XhoI fragment of plasmid pTRE2pur 
(Clontech), which contains the puromycin N-acetyl-transferase expression cassette, into 
pUC19 vector that had been modified by insertion of an oligonucleotide cassette to 
contain a single XhoI restriction site in its MCS. Beginning 1 day post-transfection, cells 
were cultured in Dulbecco’s modified Eagle medium supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin, 5 mg/mL blasticidin, and 2 mg/mL 
puromycin for 3 weeks. The surviving cells were treated with 3 mg/mL doxycycline for 1 
day before being sorted for EGFP fluorescence and surface expression of HA-ββ detected 
by anti-HA antibody (Sigma-Aldrich/Merck, Darmstadt, Germany). The cells stably 
expressing BirA/HA-GPIbβ/EGFP were further transfected with the pBIG5b- Iba/IX-
biotag/mCherry vector, cultured for 3 weeks, and sorted for stable surface expression of 
GPIbα detected by WM23, and EGFP and mCherry fluorescence. Alternatively, cells 
stably expressing HA-GPIbβ/BirA/EGFP were transiently transfected with pcDNA-Iba-
biotag and pcDNA-IX using Lipofectamine 2000. The cells were cultured in the FBS-free 
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medium containing 3 mg/mL doxycycline and 100 mM D-biotin for 1 day. The cells 
were harvested and lysed in the lysis buffer (1% Triton X-100, 5 mM CaCl2, 58 mM 
sodium borate, 10% protease inhibitor cock- tail, 5 mM N-ethylmaleimide, pH 8.0; at 
approx. 1-2 3 104 cells/mL).  
2.2. VWF A1 Domain 
        Recombinant hexahistidine-tagged VWF A1 domain was made as described in [13], 
and the VWF monomer was bought from Sino Biotech Inc.  
2.3.  Antibodies 
        Antibody WM23 and 5G6 was kindly shared by Dr. Renhao Li. The vWF D domain 
antibody (mouse monoclonal IgG1, 845 ~ 949) from Santa Cruz Biotechnology was 
coupled with the vWF monomer. The Fab kit from Piece was also employed to make Fab 
version of antibodies. 
2.4.  Botrocetin 
        The botrocetin was shared by Dr. Renhao Li with the concentration of 50 µg/ml in 
10mM Tris-buffered saline (TBS) buffer, pH 7.4. 
2.5.  DNA Handles 
        The DNA handles have been made by following the same protocol in [13]. Two 
802-bp DNA handles were generated by PCR with Vent DNA polymerase (New England 
Biolabs) in 20 mM DTT with pGEMEX 1 plasmid DNA as template (Promega) and the 
primer 5’thiolmodifier C6-SS- CGA-CGA-TAA-ACG-TAA-GGA-CAT-C and either 
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5’biotin- or 5’digoxigenin-CAA-AAA-ACC-CCT-CAA-GAC-CC primers (concentration 
= 1 µM). Next, handles were activated and coupled to protein through disulfide bonds. 
The PCR products (10 ml) were then purified by using HiSpeed Plasmid Maxi Kit 
(Qiagen) according to the manufacturer’s protocol with the following modifications. PCR 
reaction product was diluted 10-fold with QBT buffer (Qiagen) and loaded into pre-
equilibrated Qiagen HiSpeed Maxi Tips. Tips were washed with 60 ml of Buffer QC to 
remove DTT. After that, the DNA (bound in the tips) was eluted with 15 ml of QF buffer 
and immediately mixed with 0.3 ml 50 mM 2,2’-dithio-dipyridine (DTDP) in DMSO to 
activate the 5’thiol. Kinetics of release of pyridine-2-thione following activation by 
DTDP was monitored by absorbance at 343 nm. Derivatized DNA was purified to 
remove excess DTDP by precipitation with 10.5 ml isopropanol, followed by passing 
through QIAprecipitator module, with three wash applications of 2 ml 70% ethanol. 
Derivatized DNA was eluted with 1 mM EDTA in water (pH 8), concentrated 10-fold, 
and stored at -80°. Typically, the vWF antibody Fab (50 µL) was treated with 1 mM DTT 
for 1 hour at room temp. DTT was removed by passing the solution twice through 0.5 ml 
7KDa Zeba desalting columns (Pierce). About 5 µM antibody solution reacted with 10 
µM DTDP-activated DNA handles in 0.2M sodium acetate at pH 5 for 16 hours. Coupled 
sample (typically 75 µL) was neutralized by adding 8.3 µL 1 M Tris pH 8.5, and stored at 
-80°. 
2.6.  Beads for Optical-tweezers 
        Carboxyl-polystyrene 2.0 µm beads (10 mg, Spherotech, Lake Forest, IL) have been 
used in all the optical-tweezers experiments. 
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2.7 Setup for the Pulling Assay on The Optical-Tweezers Platform 
2.7.1. Functionalization of the Beads 
        Similar to the AFM experiments discussed in Chapter 2, the Carboxyl-polystyrene 
2.0 µm bead has to be functionalized to establish bioaffinites that can immobilize target 
samples. The detailed protocol is as follows: 
1. Add 10 µl of the Carboxyl-polystyrene 2.0 µm beads into 1.5ml Eppendorf Tube. 
2. Centrifuge at 720G for 5 min, discard the supernatant. 
3. Dissolve with 0.4 ml PolyLink Coupling Buffer (Polysciences. Inc) 
4. Repeat 2-3-2 for 2 times. 
5. Add 0.2 ml PolyLink Coupling Buffer to dissolve 
6. Freshly prepare 200 mg/ml EDAC solution: 7 mg EDAC+35ul PolyLink 
Coupling Buffer. 
7. Add 10 µl EDAC solution from 6 to the beads from 5. 
8. Shake to mix well for 10min, room temperature. 
9. Add protein (Streptavidin/antibody) at about 1mg/ml concentration. 
10. Seal with Parafilm and shake to mix for 1 hour, room temperature.  
11. Centrifuge 720G for 10min. 
12. Wash 5 times with 0.4ml PBST (0.02% Tween 20) for each time. 
13. Add 0.2ml PBST (0.02% Tween 20) + 0.2 ml PBS (2mM Sodium Azide) 
14.  Store in 4oC. 
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2.7.2. Coat The DNA-Handle Coupled Sample onto The Functionalized Beads 
                Before the experiment, the functionalized beads are diluted 10-fold and the 
DNA handle-coupled protein is diluted to about 10 nM concentration and mixed with the 
beads. Resulting solutions were then mixed well and incubated for 10 min in room 
temperature. Lastly, the sample was diluted into 1ml with Tris-buffered saline (TBS) and 
loaded into a syringe. 
2.7.3. Optical-tweezers Setup 
 
 
Figure 24. Diagram of the optical-tweezers setup [76]. 
5G6	   binding	  site 
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        In the optical-tweezers pulling assay, the laser traps one bead with one of the 
samples coated on it. Typically, the vWF A1 domain is coupled with Bio-DNA handle 
and coated on this trapped bead. On the other side, the bead fixed with the micropipette is 
coated with the biotinylated GPIb-IX complex. As shown above in Figure 24, individual 
domains of GPIbα are marked on the left. 
 
3. Results and Discussion 
3.1. Optical-tweezers Unfolding Assay on VWF A1 Domain-GPIb-IX  
         During the experiment, the optically trapped bead (VWF A1 domain) was driven to 
repeat the contact-retraction cycle. For each cycle, the VWF A1 Domain was contacted 
with the GPIb-IX coated bead fixed by the micropipette for about 1 to 5 seconds at a 
preset contact force (~3 pN) and then retracted away in a constant pulling speed. A 
typical unfolding curve is shown in Figure 25.  
 
Figure 25. Typical unfolding curve of VWF A1 domain-GPIb-IX [76]. 
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        From the plot, the extension length of the tether is about 200nm. Taking the 
stretching of the DNA handle and the length of the complex into account, the entire 
extension agrees with the structure of our samples. Furthermore, at the end of the tether, 
the rupture force (about 10-15pN) is comparable with previously reported results in [86]. 
Thus the binding strength is relatively weak here, but the result is even more reasonable 
by considering the physiologic environment in the circulating system. The self-truncation 
of VWF (by ADAMTS13) has been discussed; coupled with the affinity between VWF 
and GPIb-IX, they are serving as the safety factor to prevent the vessel from thrombosis. 
In sum, the implementation of optical-tweezers experiment to measure the binding 
affinity between VWF A1 Domain and GPIb-IX complex at the single- molecule level is 
very successful. 
 
3.2. Locate the Mechanosensitive Domain (MSD) within GPIb-IX Complex 
        Based on the result of the unfolding assay, it has been conformed that there is a 
domain within the GPIb-IX complex, which can rapidly respond to the external 
mechanical stimulation and transfer this signal through the entire molecule. Here we 
named this domain as Mechanosensitive Domain (MSD). After we learned the 
mechanical properties of MSD from previous unfolding assay, another question is even 
more important to be studied: where is the mechanosensitive domain located within the 
GPIb-IX complex? We then narrowed down the scope by running the unfolding assay on 
different regions of GPIb-IX. Finally, as reported in [76], a so-called stock region 
exhibits same unfolding properties as we measured from VWF A1-GPIb-IX. To further 
 67 
confirm the location of MSD is in the stalk region, two antibodies are employed here to 
locate the MSD.  
        As shown in Figure 24, the WM23 antibody binds on the middle of the 
macroglycopeptide region. Comparably, another antibody 5G6 binds with some sites 
inside the stalk region. Hereby, these two different antibodies were coupled with DNA 
handle and then coated on the avidin bead. We then drove the antibody-coated beads to 
pull the GPIb-IX complex. If the mechanosensing domain (MSD) that can perform 
outstanding elasticity to process the mechanical stimulation is in the stalk region, the 
unfolding spectrum with WM23 and 5G6 antibodies should be different. The unfolding 
curves are shown in Figure 26. 
 
                                                                                 
Figure 26. Unfolding curves of GPIb-IX with WM23 and 5G6 antibodies. 
 
        Comparing the unfolding curves in Figure 26, the unfolding extension is very 
different from each other, which agrees with our hypothesis. Since the WM23 is bound 
outside the stalk region, the optical-tweezers were pulling apart the entire stalk region. 
For 5G6, the optical-tweezers were pulling a part of the stalk region due to the 5G6 
Extension: ~6nm 
WM23 5G6 
Extension: ~15nm 
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antibody bound inside. After analyzing all the data, the average unfolding extensions of 
WM23 and 5G6 are compared in Figure 27. As the bars illustrate, when pulling with 
WM23 antibody, the GPIb-IX gives about 2-fold unfolding extension compared to the 
5G6 antibody. This experimental result gives direct evidence to prove the 
mechanosensitive domain (MSD) is the stalk region of GPIb-IX complex. 
 
 
Figure 27. Average unfolding extension of GPIb-IX pulled by WM23 and 5G6.  
 
        After the mechanosensitive domain (MSD) has been located, the mechanism of the 
mechanical signal sensing and processing can be determined. As shown in Figure 28, a 
dynamic model has been proposed to describe the entire signal processing process in 
GPIb-IX. When the GPIb-IX is inactivated, the MSD in GPIbα is folded (marked in 
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Figure 28 left). After the platelet anchors on VWF, the external mechanical stimulation 
from the bleeding stream passes down to the molecule; consequently the MSD unfolds 
(shown in Figure 28 right). The stimulated conformational change in the adjacent 
extracellular domains of GPIbb and GPIX then sends a signal across the platelet 
membrane to start the aggregation process of the platelet [76]. 
 
Figure 28.  Schematic of a proposed model showing the mechanosensitive mechanism of 
GPIb-IX [76]. 
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3.3. Measure the Enhancement of Botrocetin on VWF A1 Domain-GPIb-IX 
Complex Interaction 
        By utilizing the optical-tweezers, another similar pulling assay was conducted on 
VWF monomer-GPIb-IX complex with the involvement of botrocetin. Particularly, we 
first coupled the Fab VWF D’D3 antibody (3E2D10, Santa Cruz Biotechnology) with the 
Bio- DNA handle and then linked it with the avdin bead. Next, the VWF monomer (from 
Sino Biotech Inc.) was incubated with the antibody-coated beads for 30min. On the other 
side, the GPIb-IX complex was coated on avdin beads by following the previous method. 
During the experiment, the Tris-buffered saline (TBS) buffer was used initially. The 
unbinding assay was run to record the rupture force between VWF monomer and GPIb-
IX. Afterward, the botrocetin was added into TBS with the concentration of 1µg/ml. The 
experimental buffer was then changed to TBS + botrocetin immediately. The exactly 
same unbinding assay was continued to record the rupture force under botrocetin 
enhancement. The two data groups were plotted into histogram as shown in Figure 29.      
   
Figure 29. Histograms of the rupture force when unbinding VWF monomer from GPIb-
IX with and without botrocetin. 
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Figure 30. Lifetime (s) versus Rupture force (pN) of VWF monomer-GPIb-IX without 
(top) and with (bottom) botrocetin. 
Without Bothocetin  
With Bothocetin  
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       It is shown clearly that the most probable rupture force to unbind VWF monomer-
GPIb-IX is increased after adding botrocetin into experimental buffer. With the 
botrocetin, the affinity was enhanced about two fold compared to without botrocetin. In 
the same time, based on the analysis of our data, the percentage of the unfolding of the 
stalk region was also improved by botrocetin from 32.05% to 65.88%.  The dynamic 
force spectrum was applied to both cases to determine the enhancement from kinetic 
phase. The ko (disassociation rate constant) and Δx (barrier distance) were calculated by 
fitting the data with Dudko model [87]. The lifetime (s) versus force (pN) is then plotted 
as in Figure 30. The parameters are compared in Table 7. 
 
Table 7. Comparison of the Dudko model fitted parameters before and after adding 
botrocetin 
 
Sample k0  (s-1) Δx (nm) ΔG (kB) Unfolding percentage 
Without Botrocetin 0.0398615s−1 0.60nm 4.83kB 32.05% 
With Bothocetin 0.0247938s−1 0.50nm 5.96kB 65.88%.   
 
 
4. Conclusion 
        In this chapter we first present evidence for a mechanosensor region in the GPIb-IX 
complex. By conducting force-induced pulling assay on the optical-tweezers platform, 
the VWF A1 domain was driven to pull the GPIb-IX complex. Additionally, two 
antibodies that bind onto different locations within GPIb-IX complex have been applied 
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to identify the position of the mechanosensor. Work here demonstrates conclusively that 
the mechanical sensing domain is localized to the stalk region of GPIbα.  
        Meanwhile, based on the setup of this experiment, the enhancement of botrocetin on 
VWF-GPIb-IX interaction has been studied. The optical-tweezers successfully mimicked 
the physiologic environment before and after the involvement of botrocetin. Our result 
indicates the botrocetin is not only promoting the adhesive affinity between VWF and 
GPIb-IX, but also altering the mechanical property of VWF. This experiment has built a 
solid foundation for the study of hemostasis and thrombosis in the future.    
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CHAPTER 4 
Biomechanical Properties of von Willebrand Factor (VWF) 
Multimer 
1. Introduction 
        The multimeric von Willebrand Factor is one of the largest proteins in the human 
body. The multimer (> 20000 KDA) can be constructed of 250 monomers at most [88]. 
With the help of an electron microscope, people have seen the 50-fold expansion in 
length between stored VWF in WPB and the stretched form after secretion from 
endothelial cells in vitro [89]. The VWF multimer is the final functional form of VWF, 
thus its properties have the most physiological and pathologic meaning. In the present 
study, multiple experimental methods are employed to further uncover its structural and 
functional characteristics. Using these experimental methods, the VWF can be studied 
from a domain phase to a multimer phase, in that the newly discovered properties are 
more universally examined. First, on the platform of atomic force microscope (AFM), 
both unfolding and unbinding assays have been done on plasma VWF multimer, 
recombinant VWF multimer and mutant VWF multimer. The result will be compared 
with those acquired from the VWF monomer and the single domains. Second, 
microfluidic devices are utilized. Since the stretched VWF multimer is of an ultra-large 
size, it can be observed easily under fluorescent microscope. The benefit of this method is 
that the experiment can be conducted in a real time and the conformational change can 
then be recorded in a real time. Finally, the optical-tweezers have also been employed to 
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probe the sophisticated intramolecular interactions within the VWF multimer. A novel 
assay with double antibodies has been developed for this topic.   
 
2. Materials and Methodology 
2.1. VWF multimer 
        The plasma VWF multimer is purchased from CALIBIOCHEM Company. The 
recombinant VWF monomer is processed by SINO Biotech, Inc. Dr. Thomas A. J. 
McKinnon supplies us with the recombinant wild type VWF multimer and the mutant 
VWF multimers. 
        The plasma VWF multimer is fluorescently labeled with Alexa 488 (Thermo 
Fisher Alexa Fluor® 488 Microscale Protein Labeling Kit A30006) and biotinylated 
with Biotin-xx Microscale Protein Labeling Kit B30010 from Thermo Fisher. 
 
2.2. Microfluidic Flow Chamber 
        The PDMS chamber was made in Dr. Xuanhong Cheng’s lab with Oxygen 
plasma treatment. Afterward, the functionalization process was performed inside the 
chamber by following the protocol below: 
1. Use glass syringe to inject aceton into the chamber and soak it for 5 min to 
clean. 
2.  Clean by UV/plasma cleaner for 20 min. 
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3. Use syringe to inject 2% APTES (200ul APTES, 8.8ml isopropyl alcohol, 1ml 
DI water) into the chamber and incubate the device in a clean petri dish sealed 
with Parafilm for 15min in room temperature. 
4. Wash the chamber 5 times by injecting fresh DI water into it. 
5. Freshly prepare 0.1% glutaraldehyde solution (8ul 25% glutaraldehyde, 2ml 
PBS). 
6. Inject the 0.1% glutaraldehyde solution form 5 into the chamber and then 
incubate for 30 min in clean petri dish sealed with Parafilm. 
7. Dry by flowing nitrogen gas through the chamber. 
8. Inject the protein solution, for example collagen, into the chamber and 
incubate for at least 1 hour in room temperature. Put it in clean petri dish and 
seal carefully with Parafilm. 
9. Before conducting experiment, inject 50mM ethanolamine solution (in Tris 
buffer, pH 7.5) and incubate for 15 min to quench the free aldehyde group. 
10. Wash with experimental buffer of selection.   
 
2.3 Antibodies and DNA Handles 
        Two gelatin free VWF antibodies are used in this study. Both of them are 
purchased from Santa Cruz Biotechnology, Inc: the D’D3 monoclonal antibody 
(3E2D10) binds between amino acids 845 and 949 of the mature VWF and the C-
terminus antibody (C-12) binds between amino acids 2779 and 2813 near the C-
terminus of VWF. The antibodies are then treated with the Pierce™ Fab Preparation 
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Kit (Thermo Scientific 44985) to generate the fragment antigen binding (Fab 
fragment) to strengthen the specification of the selected binding sites. 
 
3. Results and Discussions 
3.1. Unfolding the VWF Multimer with Atomic Force Microscope (AFM)  
 
 
Figure 31. Unfolding the plasma AFM multimer. a. AFM Force-Extension curve of 
VWF multimer. b. AFM Force-Extension curve of VWF monomer. 
 
        We employed a single-molecule pulling and force-clamp measurements to better 
understand the details of intramolecular unfolding behavior and then relaxation of VWF 
multimer at a single molecule level. The plasma VWF multimer is immobilized on a 
gold-coated surface. On the other side, the AFM cantilever is coated with polylysine. 
Running the force-scanning mode with our homebuilt AMF, the individual VWF 
multimer has been stretched in a perpendicular direction. As shown in Figure 31a, force-
extension curve illustrates the fully unfolding of the VWF multimer. While comparing 
Fig.3. (A) Representative AFM retract trace of stretching a single vWF. Dashed line 
indicates no applied force. Areas above the trace are labeled with possible conformations 
of vWF at different stages. (B) shows representative AFM retract and approach traces of 
stretching a short single vWF.
A B I II IIIa b 
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with the conformational change of the VWF, we can divide the entire elongation process 
into three stages. In stage one, the VWF multimer is in compact shape and adheres just to 
the cantilever tip. As shown by the dash line, in this stage the compact VWF is able to 
withstand a force around 100 pN. Afterwards, the process comes to the second stage. The 
biopolymer starts local unfolding and the contour length of VWF increases steadily. 
Based on previous study reported in Ref [13], A2 domain of VWF can achieve 10 to 20 
pN unfolding force before it is ruptured. Thus the saw-tooth patterns in this stage indicate 
the unfolding of the domains. Finally, in stage three, the entire VWF is fully stretched. 
Force-extension curve in Figure 31a suggested a contour length of about 1.2 µm which 
agrees with the EM result of fully extended VWF [90].  Furthermore, by recalling Hook’s 
Law, the spring constant can be estimated in the order of 1 mN/m. Comparably, as shown 
in Figure 31b, the monomeric VWF exhibits a contour length of about 75nm. But the 
spring constant is a little higher than multimer, about 2mN/m. The length of a fully 
extended VWF monomer has been reported to be around 80nm [4, 5, 91]. 
 
3.2. Characterization of the Interaction between VWF and Collagen under Shear 
Flow 
        Previous studies have shown that the shear flow can alter the conformation of VWF 
[17, 92, 93]. However, questions such as: what is the most essential cause of VWF’s 
unique hydrodynamic behavior, does the conformational change dependents on the 
adhesive affinity between VWF and collagen still remain unclear. In order to answer 
these questions, we employ fluorescent microscope to directly visualize the unfolding 
 79 
behavior of an individual VWF multimer in a microfluidic channel under controlled 
hydrodynamic field. By measuring the rates of attachment to inner surface and recording 
the conformational changes in a real time, at the moment that VWF becomes attached on 
the collagen coated wall, the result may be able to answer if the adhesion is proportional 
to the shear rate and/or the altered conformation.  
 
 
Figure 32. Microfluidic System to Achieve Controllable Flow Field. a. Schematic of 
microfluidic Chamber made of PDMS. b. Fluorescent VWF attached under no/slow flow. 
c. Fluorescent VWF attached under high shear flow. d. Attachment of VWF vs. 
displacement distance in chamber (5000 s-1). 
 
         As shown in Figure 32a, we applied a homebuilt microfluidic channel into the 
force-induced flow experiment to study the flow-dependent interaction between VWF 
multimer and collagen. A Harvard Apparatus Syringe pump was utilized to precisely 
adjust the shear rate [94]. The inner chamber was salinized with APTES [95], conjugated 
with glutaraldehyde and then coupled with human collagen type I at last. Because of the 
formation of covalent bond, durability of the functional coating layer (collagen type I) is 
strengthened significantly. The VWF multimer used in this experiment is from human 
a 
b
 
c 
d
a 
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plasma and labeled with Alexa 488 fluorescence dye, and then diluted into PBS to the 
concentration of 5um/ml for experiment. 
        From the observation via fluorescent microscope, as shown in Figure 32b and c, it 
was revealed that the VWF exhibited a compact globular conformation. The VWF could 
still adhere onto the collagen coated surface when there is little or no-shearing applied. 
While applying high shearing in the flow channel (5,000 s-1), The VWF stretched to an 
elongated shape by the hydrodynamic force and attached onto the collagen-coated 
surface. By comparing Figure 32b and c, it is obvious that the attached VWF multimer 
changed size from about 2um compact shape to over 10um in length. After carefully 
checking the entire high shear flow test section (the narrow part in the middle) of the 
channel, we obtained the distribution of the adhered VWF vs. the displacement of 
particles along the shear flow direction of our microfluidic chamber, as shown in Figure 
32d. From the histogram it is estimated that the attachment rate of VWF multimers under 
applied high shear flow. At the early stage when the coiled VWF molecules just go into 
high shear rate flow, they need time to react. Because the globular shaped partials tend to 
concentrate in the middle of the flow. Shortly, they elongate after experiencing high 
shearing for a little while, and migrate to the wall. This is the moment when the 
attachment increases sharply. Another important reason is that the exposure of the A3 
domain has a strong interaction with collagen type I. The attachment decreases because 
the shear rate becomes lower so that it cannot maintain the extension of the stretched 
VWF multimers. The implementation of this flow experiment established a very good 
observation method for large molecules. Even though the conformational change of VWF 
multimer could not be observed in a real time in the present study, this system is still very 
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applicable for further study when the mechanical properties of VWF is better understood 
from the study of intramolecular interaction.  
3.3. Characterization of the Domain-Domain Interactions within the VWF Multimer  
        Recalling the result from the VWF multimer unfolding experiment, as shown in 
Figure 31a, there are several unknown force resistances during the second stage of VWF 
multimer stretching. Zhang et al. [13] characterized the unfolding of A2 domain as saw-
tooth patterns in a force-extension curve. Another interesting phenomenon has been 
reported in References [92, 93] that when the VWF is not immobilized, the D’D3 
domains are shielding the A1 domain in a way in which the adhesion between the VWF 
and the platelet is inhibited, as illustrated in Figure 33 with a schematic. The recent study 
[94] indicated that this inhibition could also be due to the interaction between A1 and A2 
domains. Thus the intramolecular interaction of VWF is very important to understand the 
dynamic mechanism of the VWF multimer. The intramolecular interaction is a very 
sophisticated mixture of both structural and functional sub-problems. Consequently, the 
best way to conduct the study on it is starting with the simplest structure and then adding 
more and more puzzle pieces until the entire multimeric structure is constructed.  
 
 
Figure 33. Schematic of domain-domain interactions. 
  
 
 
  
D’D3 domains shields A1 domain 
A1 binds with A2 
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        Here a unique assay method was developed to unfold the VWF-the antibody-based 
pulling assay. This experimental method is designed for the VWF specifically, because 
two VWF antibodies are employed here to locate the selected portion that will be 
unfolded in later steps. The schematic depicted in Figure 34 helps revealing the basic 
setup of this method. The D domain antibody and C-terminus antibody are truncated by 
the papain column and then purified to obtain the Fab fragments. By utilizing the same 
method as described in Chapter 3, the C-terminus antibody is coupled on the surface of 
the polystyrene 2.0 µm beads that will be immobilized on the micropipette of the optical 
tweezers later. On the other side, the same beads are first coated with streptavidin and 
then coupled with the biotinylated DNA handle (following the protocol in Chapter 3). 
The D domain antibody Fab is linked with the DNA handle by Traut’s reagent (Life 
Technologies).     
 
 
Figure 34. Schematic of the antibody-based pulling assay. 
 
        Based on the work done by Zhang, et al. [13], the mechanical properties of A2 
domain within the VWF has been fully characterized. Thus the unfolding of A2 domain 
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can be distinguished easily on the pulling curve by the antibody-based pulling assay. 
With this approach, the domain-domain interactions can be filtered out from the pulling 
curve and will be analyzed separately. This method was first applied to unfold the VWF 
monomer. The resultant pulling curves are shown in Figure 35. In panel a of the figure, 
the pulling curve with only A2 unfolding is compared against the pulling curve reported 
in Ref [13].  Both of the extension and the unfolding force are very similar. At this point, 
the A2 unfolding in the resultant pulling curves can be determined. In panel b and c, 
besides the A2 unfolding, another unfolding dips are shown either above the A2 
unfolding or below it. In panel d all three kinds of unfolding appear together. 
 
  
 
 
a 
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b 
 
c 
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Figure 35. Pulling VWF monomer with the antibody-based pulling assay. a. A2 domain 
unfolding only, comparing with literature. b. Domain-domain interaction above A2 
unfolding. c. Domain-domain interaction below A2 unfolding. d. Domain-domain 
interactions show both above and below the A2 unfolding. 
 
        Pulling VWF with the antibody-based method is the first experiment in the field that 
is examining the domain-domain interactions on a single-molecule level. When the result 
of literature [92, 93] in a dynamic way is considered, the shielding effect between D’D3 
domain and A1 domain doesn’t influence the unfolding of A2 domain. Thus the D’D3-
A1 interaction can appear either before the A2 unfolding or after. Meanwhile, the A1-A2 
interaction reported in Ref [94] does involve the A2 domain. Consequently, the unfolding 
of A1-A2 interaction has to be before the A2 unfolding. This leads to the conclusion that 
d 
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the antibody-based pulling assay is capable to capture the domain-domain interactions. 
However, to identify and characterize each interaction, a greater number of experiments 
are needed. Also, pulling the entire monomer is preliminary and quantitative.  The similar 
assays can be conducted on shorter fragments of the VWF to precisely locate and 
characterize the domain-domain interaction. 
     
4. Conclusion 
        Within this chapter, our research target has been scaled up from domain interactions 
to the multimeric structure. The unfolding assay on plasma VWF multimer suggested 
extremely complicated intramolecular structure of the VWF multimer. Different stages of 
the VWF conformational change have been categorized and the required force level was 
finally related to each stage. The result drew a big map of VWF multimer, which 
successfully oriented the following experiments. Next, another map was brought to us by 
the microfluidic flow experiment. The fluorescently labeled VWF multimer showed that 
the rough relationship between the structure and adhesive function exist. Afterward, the 
AFM unbinding assay was conducted on VWF mutations and the force spectrum of each 
sample pair was put together showing up a good comparison and summary. From the 
results, the mechanical properties of each mutation are quantified. The pathologic 
observations were then connected firmly with physical indicators. This established 
methodology has tremendous potential to study biological systems, because it initialized 
a standard to normalize the bio-affinities. Compared with the traditional biology analysis 
that has been used for many years, the single molecule measurement is much more 
accurate. The multidisciplinary study on biological objectives will be increasingly 
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beneficial on the development of biotechnology in the future.  Last but not the least, the 
antibody-based method on the optical tweezers platform delivered very good results that 
agreed with previous study. However, it is difficult to find proper antibodies that are able 
to pull any designated fragments from within the VWF multimer. Therefore, in its current 
stage, it is challenging to precisely locate the intromolecular interactions.   
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CONCLUDING REMARKS AND OUTLOOK 
        The research work discussed in this dissertation has systematically studied the 
structure and function of von Willebrand factor (VWF) from domain level to multimer 
level. With multiple single molecule methods, we study the conformational change 
intermolecular interaction and intramolecular interactions. The result helps us understand 
the mechanical properties of VWF as an adhesion mediator. Consequently, we tread 
VWF as a mechanical system, and utilize the resultant information to simulate it 
artificially. On the other hand, with the presence of external ligands such as Collagen, 
platelets GpIb and Factor VIII, we study the interactions from the pathologic and 
biological perspectives. In this way, we understand the function of this unique human 
protein better and use our result to solve clinical problems. At last, with the presence of 
both force and ligands, the research will be increasingly close to what is actually 
happening in human body. 
        Firstly, we started with the VWF A3 domain- collagen interaction. By applying 
AFM unbinding assay, we successfully measured the strength of the bond in between. 
The force spectrum gave us the ability to quantify the energetic properties of the VWF 
monomer-collagen bond and the VWF A3 domain-collagen bond. From the comparison, 
it was convincing that the A3 domain is the dominant binding site of collagen within 
VWF and the A1 domain didn’t contribute to binding with collagen. The Arrhenius Plot 
was a novel method to study the bioaffinities. At this point, we calculated the activation 
energy of the VWF A3 domain-collagen bond. These parameters are extremely desirable 
for researchers conducting simulation study on biological objectives. 
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        Secondly, as the other end of the VWF “bridge”, the interaction with GPIb-IX 
complex has been examined from mechanical perspective. By smartly introducing the 
definition of mechanosensor into the biological structure, we were able to predict, 
describe and manipulate the biological behaviors of the GPIb-IX complex. The signal 
transmission and processing functions of the mechanosensitive domain in GPIb-IX were 
determined by the unfolding assay. Based on that, using two antibodies with different 
binding locations, the mechanosnsitive domain has been located in the stalk region.  The 
result uncovers the dynamic mechanism of the platelet activation procedure, which is 
very helpful to the future studies on hemostasis and thrombosis. Additionally, the 
enhancing effect of botrocetin has been quantified and compared with normal condition. 
The influence is very obvious, showing the enhancement promotes the VWF A1 domain- 
GPIb-IX interaction with two folds.    
        Finally, our research was given clinical background by involving with pathological 
mutations. Within this part of the reach work, 3 mutant VWF  multimers and the Nem 
treated VWF multimer have been measured with single molecule studies. The adhesive 
function between VWF and collagen was kept the same from domain phase to multimer 
phase. The mechanical properties of the VWF mutations are consistent with the clinical 
observations of these VWD mutations. The result provides very important information to 
developing therapeutic treatment and devices of VWD and thrombosis.      
        There is no doubt that a lot of outstanding research work has been done in this 
dissertation on domain phase and monomer phase. However, at multimer lever, the 
intramolecular mechanism still remains mysterious. To continue with what have been 
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done here, the future work can be focused on the domain-domain interaction of VWF 
multimer. The Howarth Group at Oxford University has found a very interesting covalent 
binding pair [94], which is named SpyTag-SpyCatcher complex. By employing this 
technique, it is possible to truncate different fragments from VWF structure [95] . AFM 
or optical tweezers will be the preferred tools to conduct measurement on the truncations. 
Moreover, the established antibody-based pulling assay can by utilized as a diagnostic 
method to characterized the plasma VWF sample directly from patience, especially for 
those with deficient A2 domain. Lastly, the intramolecular study can supply local 
information to modeling and simulation work. The mechanical properties of domain-
domain, monomer-monomer and dimer-dimer interactions can be converted into the 
parameters of the intra-potentials, which will be very helpful to simulating the dynamic 
behaviors of VWF as a biopolymer.  
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